<SEC-DOCUMENT>0001144204-18-053807.txt : 20181015
<SEC-HEADER>0001144204-18-053807.hdr.sgml : 20181015
<ACCEPTANCE-DATETIME>20181015145909
ACCESSION NUMBER:		0001144204-18-053807
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20181010
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181015
DATE AS OF CHANGE:		20181015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		181122066

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv504760_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
October 10, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SYNTHETIC
BIOLOGICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">incorporation)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9605 Medical Center Drive, Suite 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices and
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code<B>:&nbsp;(301) 417-4364</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">N/A&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.2pt; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-indent: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 52%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<FONT STYLE="background-color: white">&nbsp;</FONT>&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01. Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October
10, 2018, Synthetic Biologics, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), entered into an underwriting
agreement (the &ldquo;Underwriting Agreement&rdquo;) with A.G.P./Alliance Global Partners, as representative of the
underwriters (the &ldquo;Underwriters&rdquo;), pursuant to which the Company agreed to issue and sell to the Underwriters in
a firm commitment underwritten public offering (the &ldquo;Offering&rdquo;) an aggregate of (i) 2,520,000 Class A Units
(the &ldquo;Class A Units&rdquo;), with each Class A Unit consisting of one share of the Company&rsquo;s common stock, par
value $0.001 per share (the &ldquo;Common Stock&rdquo;), and one five-year warrant to purchase one share of Common Stock at
an exercise price of $1.38 per share (each a  &ldquo;Warrant&rdquo; and collectively, the &ldquo;Warrants&rdquo;), with
each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the
 &ldquo;Class B Units&rdquo;, and together with the Class A Units, the  &ldquo;Units&rdquo;), with each Class B Unit offered
to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company&rsquo;s Series
B Convertible Preferred Stock (the &ldquo;Series B Preferred Stock&rdquo;), with a stated value of $1,000 and convertible
into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B
Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of
13,672,173 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant
to the Underwriting Agreement, the Company granted the Underwriters a 45 day option (the &ldquo;Over-allotment Option&rdquo;)
to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825
shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company
additional Warrants to purchase 1,807,826 shares of Common Stock. The Offering, including the Warrants purchased in the partial
exercise of the over-allotment option, closed on October 15, 2018. The Units were not certificated and the shares of Common Stock,
Series&nbsp;B Preferred Stock and Warrants comprising the Units are immediately separable and were issued separately in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Units were offered
by the Company pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-227400), as amended, filed with
the Securities and Exchange Commission (the &ldquo;Commission&rdquo;), which was declared effective by the Commission on October
10, 2018 (the &ldquo;Registration Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The conversion price
of the Series&nbsp;B Preferred Stock and exercise price of the Warrants is subject to appropriate adjustment in the event of recapitalization
events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&rsquo;s
Common Stock. The exercise price of Warrants is subject to adjustment in the event of certain dilutive issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants are
immediately exercisable at a price of $1.38 per share of Common Stock (which is 120% of the public offering price of the
Class A Units) and will expire on October 15, 2023. If at the time of exercise, there is no effective registration statement
registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the
Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection
with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the
fractional amount multiplied by the fair market value of any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may not
effect, and holder will not be entitled to, exercise any Warrant or conversion of the Series B Preferred Stock, which, upon giving
effect to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the holder (together
with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding
immediately after giving effect to the exercise, or (ii) the combined voting power of the Company&rsquo;s securities beneficially
owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting
power of all of the Company&rsquo;s securities then outstanding immediately after giving effect to the exercise or conversion,
as such percentage ownership is determined in accordance with the terms of the Warrants or Series B Preferred Stock. However, any
holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days&rsquo; prior
notice from the holder to us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds to
the Company from the Offering, after deducting the Underwriters&rsquo; fees and expenses and the Company&rsquo;s estimated Offering
expenses, and excluding the proceeds, if any, from the exercise of the Warrants issued in the Offering, are expected to be approximately
$16.7 million.&nbsp;The Company anticipates using the net proceeds from the Offering to fund the Company&rsquo;s and its subsidiaries&rsquo;
preclinical and clinical programs, (including, but not limited to, providing approximately $5.0-$7.0 million in funding for manufacturing
scale-up activities to progress SYN-004 towards a potential Phase 3 clinical trial (broad indication) and/or initiate a Phase 1/2
clinical trial(s) in a specialty population, approximately $7.5 million in funding for preclinical development and related manufacturing
activities for the Company&rsquo;s IND and Phase 1 clinical trial for the Company&rsquo;s SYN-020 program and required milestone
payments) and for working capital and general corporate purposes, including, to acquire, license or invest in complementary businesses,
technologies, product candidates or other intellectual property.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Underwriting Agreement
contains representations and warranties that the parties made to, and solely for the benefit of, the other in the context of all
of the terms and conditions of that agreement and in the context of the specific relationship between the parties.&nbsp;The provisions
of the Underwriting Agreement, including the representations and warranties contained therein, are not for the benefit of any party
other than the parties to such agreements and are not intended as documents for investors and the public to obtain factual information
about the current state of affairs of the parties to those documents and agreements. Rather, investors and the public should look
to other disclosures contained in the Company&rsquo;s filings with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company also entered
into a warrant agency agreement with its transfer agent, Corporate Stock Transfer, Inc., who will act as warrant agent for the
Company, setting forth the terms and conditions of the Warrants sold in the Offering (the &ldquo;Warrant Agency Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing summaries
of the terms of the Underwriting Agreement, the Warrant Agency Agreement and Warrants are subject to, and qualified in their entirety
by reference to, the Underwriting Agreement and the Warrant Agency Agreement (including the form of Warrant), which are filed as
Exhibits 1.1, and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
Offering, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock
(the &ldquo;Certificate of Designation&rdquo;) on October 10, 2018, with the Secretary of State of the State of Nevada that became
effective upon filing and filed an amendment to the Certificate of Designation on October 12, 2018 with the Secretary of State
of the State of Nevada that became effective upon filing. The Certificate of Designation provides for the issuance of the shares
of Series B Preferred Stock. With certain exceptions, the shares of Series B Preferred Stock rank on par with the shares of the
Common Stock, in each case, as to dividend rights and distributions of assets upon liquidation, dissolution or winding up of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With certain exceptions,
as described in the Certificate of Designation, the shares of Series B Preferred Stock have no voting rights. However, as long
as any shares of Series B Preferred Stock remain outstanding, the Certificate of Designation provides that the Company shall not,
without the affirmative vote of holders of a majority of the then outstanding shares of Series B Preferred Stock, (i)&nbsp;alter
or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend the Certificate of
Designation, (ii)&nbsp;amend the Company&rsquo;s articles of incorporation or other charter documents in any manner that adversely
affects any rights of the holders, (iii)&nbsp;increase the number of authorized shares of Series B Preferred Stock, or (iv)&nbsp;enter
into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each share of Series B
Preferred Stock is convertible at any time at the holder&rsquo;s option into a number of shares of Common Stock (subject to adjustment
for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions as specified in the Certificate
of Designation) at a conversion price equal to the stated value of the Series B Preferred Stock of $1,000 divided by the public
offering price of the Class A Units in the Offering. Holders of Series B Preferred Stock are prohibited from converting Series
B Preferred Stock into shares of Common Stock if, as a result of such conversion, the holder, together with its affiliates, would
own more than 4.99% of the total number of shares of Common Stock then issued and outstanding. However, any holder may increase
or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days&rsquo; prior notice from the holder
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Shares of the Series B
Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Company&rsquo;s board
of directors. Subject to any senior rights of the Company&rsquo;s Series A Preferred Stock, the holders of the Series B Preferred
Stock will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of Common Stock. The Company
is not obligated to redeem or repurchase any shares of Series B Preferred Stock. Shares of Series B Preferred Stock are not otherwise
entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The terms of the Series
B Preferred Stock are set forth in the Certificate of Designation, as amended, are not complete and are qualified in its entirety
by reference to the full text which is filed as Exhibit&nbsp;3.1 and Exhibit 3.2 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 10, 2018, the
Company issued a press release announcing the pricing of the Offering. On October 15, 2018, the Company issued a press release
announcing the closing of the Offering. A copy of the press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively,
and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 89%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504760_ex1-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 1.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv504760_ex1-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated October 10, 2018, by and between Synthetic Biologics, Inc. and A.G.P./Alliance Global Partners, as representative of the underwriters </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504760_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 3.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv504760_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series B Convertible Preferred Stock</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504760_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 3.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv504760_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to Certificate of Designation of Series B Convertible Preferred Stock</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504760_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv504760_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agency Agreement, dated October 15, 2018, by and between Synthetic Biologics, Inc. and Corporate Stock Transfer, Inc. (including the form of warrant certificate)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504760_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv504760_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Synthetic Biologics, Inc., dated October 10, 2018 </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504760_ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 99.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv504760_ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Synthetic Biologics, Inc., dated October 15, 2018</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;October 15, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 47%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Interim Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tv504760_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">between</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SYNTHETIC BIOLOGICS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">and</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">A.G.P./ALLIANCE GLOBAL PARTNERS,</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">as Representative of the Several Underwriters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>UNDERWRITING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">New York, New York<BR>
October 10, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A.G.P./Alliance Global Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As Representative of the several Underwriters named on Schedule
1 attached hereto<BR>
590 Madison Avenue, 36<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned, Synthetic
Biologics, Inc., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates,
including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being
subsidiaries or affiliates of Synthetic Biologics, Inc., the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this
 &ldquo;<B>Agreement</B>&rdquo;) with A.G.P./Alliance Global Partners (hereinafter referred to as &ldquo;you&rdquo; (including its
correlatives) or the &ldquo;<B>Representative</B>&rdquo;) and with the other underwriters named on <U>Schedule 1</U> hereto for
which the Representative is acting as representative (the Representative and such other underwriters being collectively called
the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an &ldquo;<B>Underwriter</B>&rdquo;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD STYLE="text-align: justify"><U>Purchase and Sale of Securities</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.1</TD><TD STYLE="text-align: justify"><U>Firm Securities</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nature
and Purchase of Firm Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the
Company agrees to issue and sell to the several Underwriters, an aggregate of 2,520,000 Class A Units (each, a &ldquo;<B>Class
A Unit</B>&rdquo; and collectively, the &ldquo;<B>Class A Units</B>&rdquo;), each Class A Unit consisting of one share of the Company&rsquo;s
common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), and a warrant, in the form filed as an exhibit
to the Registration Statement (as defined in Section 2.1.1 below), to purchase one share of Common Stock (each, a &ldquo;<B>Warrant</B>&rdquo;
and collectively, the &ldquo;<B>Warrants</B>&rdquo;), and an aggregate of 15,723 Class B Units (each, a &ldquo;<B>Class B Unit</B>&rdquo;
and collectively, the &ldquo;<B>Class B Units</B>&rdquo;), each Class B Unit consisting of one share of Series B Convertible Preferred
Stock, par value $0.001 per share (the &ldquo;<B>Preferred Stock</B>&rdquo;), each share of Preferred Stock convertible into 869.5652173913043
shares of Common Stock at a conversion price of $1.15 per share, subject to adjustments, and Warrants to purchase up to 13,672,173
shares of Common Stock. Each Warrant shall be exercisable for a period of five years at an exercise price of $1.38 per share,
subject to adjustment as provided in the Warrants. The 2,520,000 Class A Units and the 15,723 Class B Units are collectively referred
to herein as the &ldquo;<B>Firm Securities</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Securities set forth opposite their
respective names on <U>Schedule 1</U> attached hereto and made a part hereof at a purchase price of $1.0695 per Class A Unit (93%
of the per Class A Unit offering price) and $930.00 per Class B Unit (93% of the per Class B Unit offering price). The Firm Securities
are to be offered initially to the public as units at the respective offering prices set forth on the cover page of the Prospectus
(as defined in Section 2.1.1 hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares
Payment and Delivery</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery
and payment for the Firm Securities shall be made at 10:00 a.m., Eastern time, on the second (2nd) Business Day following the effective
date (the &ldquo;<B>Effective Date</B>&rdquo;) of the Registration Statement (as defined in Section 2.1.1 below) under the Securities
Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;) (or the third (3rd) Business Day following the Effective Date
if the pricing for the Offering (as defined in Section 2.1.1 below) occurs after 4:01 p.m., Eastern time on the Effective Date)
or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices of Zysman, Aharoni, Gayer
and Sullivan &amp; Worcester LLP, 1633 Broadway, New York, New York 10019 (&ldquo;<B>Representative Counsel</B>&rdquo;), or at
such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by the Representative and
the Company. The hour and date of delivery and payment for the Firm Securities is called the &ldquo;<B>Closing Date</B>.&rdquo;
The Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in the form of Warrant and in a warrant
agency agreement, dated on or before the Closing Date, between the Company and Corporate Stock Transfer, Inc., as warrant agent
(the &ldquo;<B>Warrant Agreement</B>&rdquo;). The term &ldquo;<B>Business Day</B>&rdquo; means any day other than a Saturday, a
Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
for the Firm Securities shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of
the Company upon delivery of certificates (in form and substance satisfactory to the Underwriters) representing the Firm Securities
(or through the facilities of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;). The Firm Securities shall be registered
in such name or names and in such authorized denominations as the Representative may request in writing at least one full Business
Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Securities except upon tender of
payment by the Representative for all of the Firm Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.2</TD><TD STYLE="text-align: justify"><U>Over-allotment Option</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Securities</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Securities,
the Company hereby grants to the Representative an option (the &ldquo;<B>Over-allotment Option</B>&rdquo;) to purchase up to (a)
2,428,825 additional shares of Common Stock, representing fifteen percent (15%) of the shares of Common Stock sold as part of the
Class A Units and the shares of Common Stock issuable upon conversion of the Preferred Stock sold as part of the Class B Units
(the &ldquo;<B>Option Shares</B>&rdquo;), and/or (b) warrants to purchase up to 2,428,825 shares of Common Stock, representing
fifteen percent (15%) of the Warrants sold as part of the Class A Units and the Warrants sold as part of the Class B Units (the
 &ldquo;<B>Option Warrants</B>&rdquo; and collectively with the Option Shares, the &ldquo;<B>Option Securities</B>&rdquo;). The
purchase price to be paid per Option Share shall be $1.0602 and the purchase price to be paid per Option Warrant shall be $0.0093.
The shares of Common Stock issuable upon exercise of the Firm Warrants and the Option Warrants are hereinafter referred to as the
 &ldquo;<B>Warrant Shares.</B>&rdquo; The Shares of Common Stock issuable upon conversion of the Preferred Stock are hereinafter
referred to as the &ldquo;<B>Preferred Conversion Shares</B>.&rdquo; The Firm Securities, the Warrant Shares, the Preferred Conversion
Shares and the Option Securities are hereinafter referred to together as the &ldquo;<B>Public Securities</B>.&rdquo; The offering
and sale of the Public Securities is hereinafter referred to as the &ldquo;<B>Offering</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to
all (at any time) or any part (from time to time) of the Option Securities within 45 days after the Effective Date. The Underwriters
shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed
in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Securities to be
purchased and the date and time for delivery of and payment for the Option Securities (the &ldquo;<B>Option Closing Date</B>&rdquo;),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon
by the Company and the Representative, at the offices of Representative Counsel<B>&nbsp;</B>or at such other place (including remotely
by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery
and payment for the Option Securities does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice.
Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Securities, subject to the terms and
conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option Securities
specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the
total number of Option Securities then being purchased as set forth in <U>Schedule 1</U> opposite the name of such Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Securities shall be made on the Option Closing Date by wire transfer in Federal (same
day) funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the
Underwriters) representing the Option Securities (or through the facilities of DTC) for the account of the Underwriters. The Option
Securities shall be registered in such name or names and in such authorized denominations as the Representative may request in
writing at least one full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell or deliver
the Option Securities except upon tender of payment by the Representative for applicable Option Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: uppercase">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined
below), as of the Closing Date and as of the Option Closing Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.1</TD><TD STYLE="text-align: justify"><U>Filing of Registration Statement</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pursuant
to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-224039), including any related prospectus
or prospectuses, for the registration of the Public Securities under the Securities Act, which registration statement and amendment
or amendments have been prepared by the Company in all material respects in conformity with the requirements of the Securities
Act and the rules and regulations of the Commission under the Securities Act (the &ldquo;<B>Securities Act Regulations</B>&rdquo;)
and will contain all material statements that are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations. Except as the context may otherwise require, such registration statement, as amended, on file with the Commission
at the time the registration statement became effective (including the Preliminary Prospectus included in the registration statement,
financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information
deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act Regulations (the
 &ldquo;<B>Rule 430A Information</B>&rdquo;)), is referred to herein as the &ldquo;<B>Registration Statement</B>.&rdquo; If the
Company files any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the
term &ldquo;<B>Registration Statement</B>&rdquo; shall include such registration statement filed pursuant to Rule 462(b). The Registration
Statement has been declared effective by the Commission on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Each prospectus used prior
to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after
such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &ldquo;<B>Preliminary Prospectus</B>.&rdquo;
The Preliminary Prospectus, subject to completion, dated October 10, 2018, that was included in the Registration Statement immediately
prior to the Applicable Time is hereinafter called the &ldquo;<B>Pricing Prospectus</B>.&rdquo; The final prospectus in the form
first furnished to the Underwriters for use in the Offering is hereinafter called the &ldquo;<B>Prospectus</B>.&rdquo; Any reference
to the &ldquo;<B>most recent Preliminary Prospectus</B>&rdquo; shall be deemed to refer to the latest Preliminary Prospectus included
in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;<B>Applicable Time</B>&rdquo;
means 5:30 p.m., Eastern time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Free Writing
Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act Regulations
(&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405
of the Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the
Company, (ii) a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not
required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because
it contains a description of the Public Securities or of the Offering that does not reflect the final terms, in each case in the
form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s
records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer General
Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective
investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433), as evidenced by its being
specified in <U>Schedule 2-B</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Limited
Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&ldquo;<B>Pricing Disclosure
Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing
Prospectus and the information included on Schedule 2-A hereto, all considered together.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pursuant
to the Exchange Act</U>. The Common Stock is registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended
(the &ldquo;<B>Exchange Act</B>&rdquo;). The Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission
is contemplating terminating such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Exchange Listing</U>. The shares of Common Stock are listed on the NYSE American (the &ldquo;<B>Exchange</B>&rdquo;), and the Company
has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange, nor has
the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. The Company has submitted the Application for Listing of Additional
Shares with the Exchange to list the shares of Common Stock included in the Public Securities (including the Warrant Shares and
the Preferred Conversion Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Stop Orders, etc</U>. Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued any
order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted
or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied
with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosures
in Registration Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Securities Act and 10b-5 Representation. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including
the prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto,
and the Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of
the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection
with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the
Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or
at any Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits
or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading;
<I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to statements made or statements omitted
in reliance upon and in conformity with written information furnished to the Company with respect to the Underwriters by the Representative
expressly for use in the Registration Statement, the Pricing Prospectus, the Pricing Disclosure Package or the Prospectus or any
amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided by or on behalf of any
Underwriter consists solely of the following statements concerning the Underwriters (the &ldquo;<B>Underwriters Information</B>&rdquo;)
contained in &ldquo;Underwriting&rdquo; section of the Prospectus: (i) the first, second, third and sixth sentences of the section
entitled &ldquo;Discount, Commissions and Expenses&rdquo;; and (ii) the section entitled &ldquo;Price Stabilization, Short Positions
and Penalty Bids&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Pricing Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does
not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; and any Issuer Limited Use Free
Writing Prospectus hereto does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus,
the Pricing Prospectus or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken
together with the Prospectus as of the Applicable Time, did not include an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to the Underwriters Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of
any filing with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date, included, includes or
will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>,
<I>however</I>, that this representation and warranty shall not apply to the Underwriters&rsquo; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
documents incorporated by reference in the Registration Statement, the Pricing Prospectus, the Pricing Disclosure Package and the
Prospectus, when they became effective or were filed with the Commission, as the case may be, conformed in all material respects
to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder
and none of such documents contained any untrue statement of a material fact or omitted to state any material fact required to
be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Pricing Prospectus,
the Pricing Disclosure Package and the Prospectus, when such documents become effective or are filed with the Commission, as the
case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable,
and the rules and regulations of the Commission thereunder, and will not contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus conform in all material respects to the descriptions thereof contained or incorporated by reference therein and there
are no agreements or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration
Statement or to be incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus, that
have not been so described or filed or incorporated by reference. Each agreement or other instrument (however characterized or
described) to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to or incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or (ii) is material to the Company&rsquo;s
business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and
is enforceable against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms,
except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state
securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject
to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None of such
agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any
other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time
or the giving of notice, or both, would constitute a default thereunder except for a default or event which would not reasonably
be expected to result in a Material Adverse Change (as such term is defined in Section 2.5.1 below). To the Company&rsquo;s knowledge,
performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing
applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction
over the Company or any of its assets or businesses (each, a &ldquo;<B>Governmental Entity</B>&rdquo;), including, without limitation,
those relating to environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior
Securities Transactions</U>. Since September 1, 2015, no securities of the Company have been sold by the Company or by or on behalf
of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as
disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulations</U>.
The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects of federal,
state, local and all foreign regulation on the Offering and the Company&rsquo;s business as currently contemplated are correct
in all material respects and no other such regulations are required to be disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus which are not so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Other Distribution of Offering Materials</U>. The Company has not, directly or indirectly, distributed and will not distribute
any offering material in connection with the Offering other than any Preliminary Prospectus, the Pricing Prospectus, the Pricing
Disclosure Package, the Prospectus and other materials, if any, permitted under the Securities Act and consistent with Section
3.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.5</TD><TD STYLE="text-align: justify"><U>Changes After Dates in Registration Statement</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse
change in the financial position or results of operations of the Company, nor any change or development that, singularly or in
the aggregate, would involve a material adverse change, in or affecting the condition (financial or otherwise), results of operations,
business, assets or prospects of the Company (a &ldquo;<B>Material Adverse Change</B>&rdquo;); (ii) there have been no material
transactions entered into by the Company, other than as contemplated pursuant to this Agreement; and (iii) no officer or director
of the Company has resigned from any position with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities
other than securities issuable upon the exercise or conversion of then outstanding options, warrants and/or convertible securities,
or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made
any other distribution on or in respect to its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosures
in Commission Filings</U>. None of the Company&rsquo;s filings with the Commission contained any untrue statement of a material
fact or omitted to state any material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The Company has made all filings with the Commission required under the Exchange Act
and the rules and regulations of the Commission promulgated thereunder (the &ldquo;<B>Exchange Act Regulations</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Accountants</U>. To the knowledge of the Company, BDO USA, LLP (the &ldquo;<B>Auditor</B>&rdquo;), whose report is filed with the
Commission and included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the
Public Company Accounting Oversight Board. The Auditor<B>&nbsp;</B>has not, during the periods covered by the financial statements
included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, provided
to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules included or incorporated by
reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present in all material respects
the financial position and the results of operations of the Company at the dates and for the periods to which they apply; and such
financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;),
consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end
audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and
the supporting schedules included or incorporated by reference in the Registration Statement present fairly the information required
to be stated therein. The pro forma financial statements and the related notes, if any, included or incorporated by reference in
the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly compiled and prepared in accordance
with the applicable requirements of the Securities Act, the Securities Act Regulations, the Exchange Act or the Exchange Act Regulations
and present fairly the information shown therein or incorporated therein, and the assumptions used in the preparation thereof are
reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.
Except as included therein, no historical or pro forma financial statements are required to be included in the Registration Statement,
the Pricing Disclosure Package or the Prospectus under the Securities Act, the Securities Act Regulations, the Exchange Act or
the Exchange Act Regulations. The pro forma and pro forma as adjusted financial information and the related notes, if any, included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly
compiled and prepared in accordance with the applicable requirements of the Securities Act, the Securities Act Regulations, the
Exchange Act or the Exchange Act Regulations and present fairly the information shown therein, and the assumptions used in the
preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances
referred to therein. All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus,
or incorporated or deemed incorporated by reference therein, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term
is defined by the rules and regulations of the Commission), if any, comply in all material respects with Regulation G of the Exchange
Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Pricing
Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including
contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material
current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of operations, liquidity,
capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, (a) neither the Company nor any of its direct and indirect subsidiaries,
including each entity disclosed or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as
being a subsidiary of the Company (each, a &ldquo;<B>Subsidiary</B>&rdquo; and, collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than
in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind
with respect to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries,
or, other than in the course of business or any grants under any stock compensation plan, and (d) there has not been any Material
Adverse Change in the Company&rsquo;s long-term or short-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date
the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the
Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any
Option Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized,
but unissued shares of Common Stock of the Company or any security convertible or exercisable into shares of Common Stock of the
Company, or any contracts or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or convertible
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.10</TD><TD STYLE="text-align: justify"><U>Valid Issuance of Securities, etc.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Outstanding
Securities</U>. Since July 23, 2013, all issued and outstanding securities of the Company issued prior to the transactions contemplated
by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have
no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none
of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual
rights granted by the Company. The authorized shares of Common Stock conform in all material respects to all statements relating
thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the
outstanding shares of Common Stock were at all relevant times either registered under the Securities Act and the applicable state
securities or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties of the purchasers of such Shares,
exempt from such registration requirements. The description of the Company&rsquo;s stock option, stock bonus and other stock plans
or arrangements, and the options or other rights granted thereunder, as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, accurately and fairly present, in all material respects, the information required to be shown with
respect to such plans, arrangements, options and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Sold Pursuant to this Agreement</U>. The Public Securities have been duly authorized for issuance and sale and, when issued and
paid for in accordance with their respective terms, will be validly issued, fully paid and non-assessable; the holders thereof
are not and will not be subject to personal liability by reason of being such holders; the Public Securities are not and will not
be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the
Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities has been
duly and validly taken. The Public Securities conform in all material respects to all statements with respect thereto contained
in the Registration Statement, the Pricing Disclosure Package and the Prospectus. All corporate action required to be taken for
the authorization, issuance and sale of the Preferred Stock (or, with respect to the Series B Preferred Shares, will have been
taken prior to the Closing Date, including the filing of the certificate of designation of the Preferred Stock (the &ldquo;<B>Certificate
of Designation</B>&rdquo;)), the Warrants and the Option Warrants has been duly and validly taken; the Preferred Conversion Shares
and the Warrant Shares have been duly authorized and reserved for issuance by all necessary corporate action on the part of the
Company and when paid for and issued in accordance with the Certificate of Designation and the Warrant Agreement, respectively,
such shares of Common Stock will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be
subject to personal liability by reason of being such holders; and such shares of Common Stock, Preferred Conversion Shares and
Warrant Shares are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar
contractual rights granted by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the
Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include
any such securities in a registration statement to be filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Validity
and Binding Effect of Agreements</U>. This Agreement and the Warrant Agreement have been duly and validly authorized by the Company,
and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company
in accordance with their respective terms, except in each case: (i) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any
proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Warrant Agreement and all ancillary
documents related to this Offering, the consummation by the Company of the transactions herein and therein contemplated and the
compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse
of time or both: (i) result in a breach of, or conflict with any of the terms and provisions of, or constitute a default under,
or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets
of the Company pursuant to the terms of any agreement or instrument to which the Company is a party; (ii) result in any violation
of the provisions of the Company&rsquo;s Certificate of Incorporation (as the same may be amended or restated from time to time,
the &ldquo;<B>Charter</B>&rdquo;) or the by-laws of the Company (as the same may be amended or restated from time to time); or
(iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date
hereof (including, without limitation, those promulgated by the Food and Drug Administration of the U.S. Department of Health and
Human Services (the &ldquo;<B>FDA</B>&rdquo;) or by any foreign, federal, state or local regulatory authority performing functions
similar to those performed by the FDA); except in the case of clause (i) or (iii) above, for such breaches, conflicts or violations
which would not reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Defaults; Violations</U>. No material default exists in the due performance and observance of any term, covenant or condition of
any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument
evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by
which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not in violation
of any term or provision of its Charter or by-laws, or in violation of any franchise, license, permit, applicable law, rule, regulation,
judgment or decree of any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.15</TD><TD STYLE="text-align: justify"><U>Corporate Power; Licenses; Consents</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conduct
of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or as would
not result in a Material Adverse Change, the Company has all requisite corporate power and authority, and has all necessary authorizations,
approvals, orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs
as of the date hereof to conduct its business purpose as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and the Warrant Agreement
and to carry out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required in connection
therewith have been obtained. No consent, authorization or order of, and no filing with, any court, government agency or other
body is required for the valid issuance, sale and delivery of the Public Securities and the consummation of the transactions and
agreements contemplated by this Agreement and the Warrant Agreement and as contemplated by the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations
of the Exchange and the Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;)
completed by each of the Company&rsquo;s directors and officers immediately prior to the Offering (the &ldquo;<B>Insiders</B>&rdquo;),
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal shareholders as described in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined
in Section 2.27 below) provided to the Underwriters, is true and correct in all material respects and the Company has not become
aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and
incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation;
Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental
proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director, including any proceeding before the FDA or comparable federal, state, local or foreign
governmental bodies (it being understood that the interaction between the Company and the FDA and such comparable governmental
bodies relating to the clinical development and product approval process shall not be deemed proceedings for purposes of this representation),
which has not been disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus which is required
to be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Good
Standing</U>. The Company has been duly organized and is validly existing as a corporation and is in good standing under the laws
of the State of Nevada as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to
qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks
which the Company believes are adequate, and all such insurance is in full force and effect. The Company has no reason to believe
that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable
coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that
would not result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.20</TD><TD STYLE="text-align: justify"><U>Transactions Affecting Disclosure to FINRA</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Finder&rsquo;s
Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims,
payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee
by the Company or any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements
or understandings of the Company with respect to the sale of the Public Securities hereunder or, to the Company&rsquo;s knowledge,
any of its shareholders that may affect the Underwriters&rsquo; compensation, as determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments
Within Six (6) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
or the amount of fees to a FINRA members with respect to its at- market facility, the Company has not made any direct or indirect
payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee, consulting fee or otherwise, in consideration
of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company;
(ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA
member, within the six (6) months prior to the date of this Agreement, other than the payment to the Underwriters as provided hereunder
in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Affiliation</U>. Except as disclosed in their FINRA confirmations, there is no (i) officer or director of the Company, or, to the
Company&rsquo;s knowledge, (ii) beneficial owner of 5% or more of any class of the Company's securities or (iii) beneficial owner
of the Company&rsquo;s unregistered equity securities which were acquired during the 180-day period immediately preceding the filing
of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information</U>.
All information provided by the Company in its FINRA questionnaire to Representative Counsel specifically for use by Representative
Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete
in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices Act</U>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to
customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official
or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company
(or assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or penalty
in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse
Change or (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company.
The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company
to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with OFAC</U>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries, is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;),
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently subject to any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in either the Registration Statement, Pricing Disclosure Package or Prospectus has been made or reaffirmed without
a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;<B>Money
Laundering Laws</B>&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving the Company with
respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory</U>.
All preclinical studies and clinical trials conducted by or on behalf of the Company that are material to the Company and its Subsidiaries,
taken as a whole, are or have been adequately described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
in all material respects. The preclinical studies and clinical trials conducted by or on behalf of the Company and its Subsidiaries
that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are
referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still ongoing, are being
conducted in material compliance with all laws and regulations applicable thereto in the jurisdictions in which they are being
conducted and with all laws and regulations applicable to preclinical studies and clinical trials from which data will be submitted
to support marketing approval. The descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus
of the results of such studies are accurate and complete in all material respects and fairly present the data derived from such
studies, and the Company has no knowledge of, or reason to believe that, any large well-controlled clinical study the aggregate
results of which are inconsistent with or otherwise call into question the results of any clinical study conducted by or on behalf
of the Company that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results
of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received any written notices
or statements from the FDA, the European Medicines Agency (&ldquo;<B>EMA</B>&rdquo;) or any other governmental agency or authority
imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or material modification for or of any preclinical
studies and clinical trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except
as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received any
written notices or statements from the FDA, the EMA or any other governmental agency, and otherwise has no knowledge of, or reason
to believe that, (i) any investigational new drug application for any potential product of the Company is or has been rejected
or placed on clinical hold; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential
product of the Company has been, will be or may be suspended, revoked, modified or limited. To the Company&rsquo;s knowledge, the
Company and each of its directors, officers, employees and agents, is and has been in material compliance with applicable health
care laws, including, to the extent applicable, without limitation, the Federal Food, Drug and Cosmetic Act (21 U.S.C. &sect; 301
et seq.), the federal Anti-kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the civil False Claims Act (31 U.S.C. &sect; 3729 et
seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a),
the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &sect; 1320d et seq.), as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &sect; 17921 et seq.), the exclusion laws (42 U.S.C. &sect;
1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), and the Patient Protection
and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, including
without limitation the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), and the regulations promulgated pursuant to
such laws, and comparable state laws (collectively, the &ldquo;<B>Health Care Laws</B>&rdquo;). The Company has not received notice
of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental
authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws. The
Company has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments thereto as required by any Health Care Laws or Authorizations and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct and not misleading
on the date filed (or were corrected or supplemented by a subsequent submission). To the Company&rsquo;s knowledge, the manufacturing
facilities and operations of its suppliers are in compliance in all material respects with all applicable statutes, rules, and
regulations of the FDA and comparable regulatory agencies outside of the United States to which the Company or its contractors
and supplies are subject. The Company is not distributing or promoting any product in a way that would violate the advertising
and promotional requirements of the FDA or any other federal, state or foreign regulatory authority, including the FDA&rsquo;s
current regulations and policies related to &ldquo;off-label&rdquo; marketing and promotion of prescription drugs and medical devices,
consistent with the current scope of the Company&rsquo;s marketing authorization and product labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Representative
Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-Up
Agreements. Schedule 3</U> hereto contains a complete and accurate list of the Company&rsquo;s officers and directors (collectively,
the &ldquo;<B>Lock-Up Parties</B>&rdquo;). The Company has caused each of the Lock-Up Parties to deliver to the Representative
an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit A</U> <B>(</B>the<B>&nbsp;</B>&ldquo;<B>Lock-Up Agreement</B>&rdquo;),
prior to the execution of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the
conduct of business requires such qualification, except where the failure to qualify would not have a Material Adverse Change.
The Company&rsquo;s ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.29</TD><TD STYLE="text-align: justify"><U>Related Party Transactions</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.29.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Business
Relationships</U>. There are no business relationships or related party transactions involving the Company or any other person
required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not been described
as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.29.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Relationships with Customers and Suppliers</U>. No relationship, direct or indirect, exists between or among the Company on the
one hand, and the directors, officers, 5% or greater stockholders, customers or suppliers of the Company or any of the Company&rsquo;s
affiliates on the other hand, which is required to be described in the Pricing Disclosure Package and the Prospectus or a document
incorporated by reference therein and which is not so described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.29.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Unconsolidated Entities</U>. There are no transactions, arrangements or other relationships between and/or among the Company, any
of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but not
limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect
the Company&rsquo;s liquidity or the availability of or requirements for its capital resources required to be described in the
Pricing Disclosure Package and the Prospectus or a document incorporated by reference therein which have not been described as
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.29.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Loans or Advances to Affiliates</U>. There are no outstanding loans, advances (except normal advances for business expenses in
the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors
of the Company or any of their respective family members, except as disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
of Directors</U>. The Board of Directors of the Company is comprised of the persons disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus. The qualifications of the persons serving as board members and the overall composition
of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated
thereunder (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) applicable to the Company and the listing rules of the Exchange. At least
one member of the Audit Committee of the Board of Directors of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo;
as such term is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of the persons
serving on the Board of Directors qualify as &ldquo;independent,&rdquo; as defined under the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.31</TD><TD STYLE="text-align: justify"><U>Sarbanes-Oxley Compliance</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.31.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
Controls</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the
Exchange Act Regulations, and such controls and procedures are effective to ensure that all material information concerning the
Company will be made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s Exchange
Act filings and other public disclosure documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.31.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is, or at the
Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act applicable
to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company&rsquo;s future compliance
(not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accounting
Controls</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
and its Subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15
and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been designed by,
or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar
functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization;
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, the Company is not aware of any material weaknesses in its internal controls. The Company&rsquo;s auditors and
the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material
weaknesses in the design or operation of internal controls over financial reporting which are known to the Company&rsquo;s management
and that have adversely affected or are reasonably likely to adversely affect the Company&rsquo; ability to record, process, summarize
and report financial information; and (ii) any fraud known to the Company&rsquo;s management, whether or not material, that involves
management or other employees who have a significant role in the Company&rsquo;s internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to
register as an &ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Labor Disputes</U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of
the Company, is imminent. The Company is not aware that any key employee or significant group of employees of the Company plans
to terminate employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property Rights</U>. To the knowledge of the Company, the Company or its Subsidiaries owns or possesses or has valid rights to
use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations,
copyrights, licenses, inventions, trade secrets and similar rights (&ldquo;<B>Intellectual Property Rights</B>&rdquo;) necessary
for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company
or any of its Subsidiaries necessary for the conduct of its business as currently carried on and as described in the Registration
Statement and the Prospectus will involve or give rise to any infringement of, or license or similar fees (other than license or
similar fees described or contemplated in the Registration Statement, the Pricing Disclosure Package and the Prospectus) for, any
Intellectual Property Rights of others. Neither the Company nor any of its Subsidiaries has received any written notice alleging
any such infringement of, license or similar fees for, or conflict with, any asserted Intellectual Property Rights of others. Except
as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change, (i) to the knowledge
of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights
owned by the Company; (ii) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim
by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any
facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other
claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; (iii) the Intellectual Property Rights
owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company, have not been
adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the
Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such
Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that
would, individually or in the aggregate, together with any other claims in this Section 2.35, reasonably be expected to result
in a Material Adverse Change; (iv) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding
or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property Rights or other
proprietary rights of others, the Company has not received any written notice of such claim and the Company is unaware of any other
facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other
claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; and (v) to the Company&rsquo;s knowledge,
no employee of the Company is in or has ever been in violation in any material respect of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure
agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company, or actions undertaken by the employee while employed with the Company and could reasonably be expected
to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s knowledge, all material technical
information developed by and belonging to the Company which has not been disclosed in a filed patent application has been kept
confidential. The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property
Rights of any other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus
contain in all material respects the same description of the matters set forth in the preceding sentence. None of the technology
employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on
the Company or, to the Company&rsquo;s knowledge, any of its officers, directors or employees, or otherwise in violation of the
rights of any persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities
prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries
has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed
against the Company or such respective Subsidiary except as would not be reasonably expected to have a Material Adverse Change.
The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement
are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such
consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no issues have been raised (and are
currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or its
Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given
by or requested from the Company or its Subsidiaries. There are no tax liens against the assets, properties or business of the
Company or its Subsidiaries. The term &ldquo;<B>taxes</B>&rdquo; mean all federal, state, local, foreign and other net income,
gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding,
payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes,
fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional
amounts with respect thereto. The term &ldquo;<B>returns</B>&rdquo; means all returns, declarations, reports, statements and other
documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ERISA
Compliance</U>. The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security
Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<B>ERISA</B>&rdquo;))
established or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material
respects with ERISA. &ldquo;<B>ERISA Affiliate</B>&rdquo; means, with respect to the Company, any member of any group of organizations
described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published
interpretations thereunder (the &ldquo;<B>Code</B>&rdquo;) of which the Company is a member. No &ldquo;reportable event&rdquo;
(as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &ldquo;employee benefit plan&rdquo;
established or maintained by the Company or any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established or
maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would have
any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates
has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of,
or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee
benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under
Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure
to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Licenses
or Permits</U>. The Company possesses all licenses, certificates, registrations, authorizations and permits required by the FDA
and other governmental or regulatory authorities performing functions similar to those performed by the FDA and have made all declarations
and filings with, the appropriate local, state, federal or foreign governmental or regulatory agencies or bodies (including, without
limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA) that are necessary for the ownership or lease of their respective properties or
the conduct of their respective businesses as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
(collectively, the &ldquo;<B>Governmental Permits</B>&rdquo;) except where any failures to possess or make the same would not,
singularly or in the aggregate, have a Material Adverse Change. The Company is in compliance with all such Governmental Permits,
including with all conditions and limitations on the commercial rights granted by such Governmental Permits; all such Governmental
Permits are valid and in full force and effect, except where the validity or failure to be in full force and effect would not,
singularly or in the aggregate, have a Material Adverse Change. The Company has not received notification of any revocation, modification,
suspension, termination or invalidation (or proceedings related thereto) of any such Governmental Permit and the Company has no
reason to believe that any such Governmental Permit will not be renewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Laws</U>. The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations applicable
to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage or disposal of any product
manufactured or distributed by the Company (&ldquo;<B>Applicable Laws</B>&rdquo;), except as could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Change; (ii) has not received any FDA Form 483, notice of adverse
finding, warning letter, untitled letter or other correspondence or written notice from the FDA or any other governmental authority
alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B>Authorizations</B>&rdquo;); (iii)
possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation
of any term of any such Authorizations; (iv) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any governmental authority or third party alleging that any product operation or
activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental authority or
third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, except as could
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change; (v) has not received written notice
that any governmental authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations
and has no knowledge that any such governmental authority is considering such action, except as could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Change; and (vi) has filed, obtained, maintained or submitted all
material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented
by a subsequent submission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries are in compliance in all material respects with all foreign, federal, state and local
rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and
protection of health and safety or the environment which are applicable to their businesses (&ldquo;<B>Environmental Laws</B>&rdquo;),
except where the failure to comply would not, singularly or in the aggregate, result in a Material Adverse Change. There has been
no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic
or other wastes or other hazardous substances by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company&rsquo;s
knowledge, any other entity for whose acts or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon
any of the property now or previously owned or leased by the Company or any of its Subsidiaries, or upon any other property, in
violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute,
ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except
for any violation or liability which would not have, singularly or in the aggregate with all such violations and liabilities, a
Material Adverse Change; and there has been no disposal, discharge, emission or other release of any kind onto such property or
into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which
the Company has knowledge, except for any such disposal, discharge, emission, or other release of any kind which would not have,
singularly or in the aggregate with all such discharges and other releases, a Material Adverse Change. On the basis of such reviews,
the Company and its Subsidiaries have reasonably concluded that such associated costs and liabilities would not have, singularly
or in the aggregate, a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Real
Property</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
and each of its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all
items of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in
each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate,
materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by
the Company or any of its Subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries,
considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary
has received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company
or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or
such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease which would result
in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contracts
Affecting Capital</U>. There are no transactions, arrangements or other relationships between and/or among the Company, any of
its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company&rsquo;s or any of its Subsidiaries&rsquo; liquidity or the availability of or requirements for their capital
resources required to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and
the Prospectus which have not been described or incorporated by reference as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loans
to Directors or Officers</U>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the
Company, or any of their respective family members, except as disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ineligible
Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness
of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant
made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at
the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405, without taking account
of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible
issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accelerated
Filer</U>. As of the time of the initial filing of the Registration Statement and as of the date hereof, the Company was an &ldquo;accelerated
filer,&rdquo; as defined in Rule 12b-2 of the Exchange Act Regulations; however on June 30, 2018, the Company&rsquo;s non-affiliate
float was below $75,000,000 .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Industry
Data</U>. The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and
accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Margin
Securities</U>. The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the &ldquo;<B>Federal Reserve Board</B>&rdquo;), and none of the proceeds of Offering will be used,
directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause
any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings of Regulation T, U or X of
the Federal Reserve Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Act Reports</U>. The Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(a), 13(e), 14
and 15(d) of the Exchange Act during the preceding 12 months (except to the extent that Section 15(d) requires reports to be filed
pursuant to Sections 13(d) and 13(g) of the Exchange Act, which shall be governed by the next clause of this sentence); and the
Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(d) and 13(g) of the Exchange Act
since July 23, 2013, except where the failure to timely file could not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Minute
Books</U>. The minute books of the Company have been made available to the Underwriters and counsel for the Underwriters, and such
books (i) contain a complete summary of all meetings and actions of the board of directors (including each board committee) and
stockholders of the Company (or analogous governing bodies and interest holders, as applicable), and each of its Subsidiaries since
the time of its respective incorporation or organization through the date of the latest meeting and action, and (ii) accurately
in all material respects reflect all transactions referred to in such minutes. There are no material transactions, agreements,
dispositions or other actions of the Company that are not properly approved and/or accurately and fairly recorded in the minute
books of the Company, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality
and Non-Competition</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant of the Company is subject
to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer or prior employer
that could reasonably be expected to materially affect his ability to be and act in his respective capacity of the Company or be
expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stabilization</U>.
Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Representative)
has taken, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause
or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security
of the Company to facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering
to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of
any such securities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD STYLE="text-align: justify"><U>Covenants of the Company</U>. The Company covenants and agrees as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
to Registration Statement</U>. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to
the Registration Statement, Preliminary Prospectus, Pricing Disclosure Package or Prospectus proposed to be filed after the Effective
Date and not file any such amendment or supplement to which the Representative shall reasonably object in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">3.2</TD><TD STYLE="text-align: justify"><U>Federal Securities Laws</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 424(b) and Rule 430A of the Securities Act Regulations,
and will notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration
Statement or any amendment or supplement to any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus shall
have been filed and when any post-effective amendment to the Registration Statement shall become effective; (ii) of the receipt
of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or
any amendment or supplement to any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus or for additional information;
(iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment or of any order preventing or suspending the use of any Preliminary Prospectus, the Pricing Disclosure Package or the
Prospectus, or of the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e)
of the Securities Act concerning the Registration Statement; and (v) if the Company becomes the subject of a proceeding under Section
8A of the Securities Act in connection with the Offering of the Public Securities. The Company shall effect all filings required
under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without
reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus
transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly
file such prospectus. The Company shall use its best efforts to prevent the issuance of any stop order, prevention or suspension
and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange
Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and
in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to
the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;<B>Rule 172</B>&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur
or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company,
to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading;
(ii) amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus,
as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser
or (iii) amend the Registration Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case
may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly
(A) give the Representative notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement
or omission or to make the Registration Statement, the Pricing Disclosure Package or the Prospectus comply with such requirements
and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment
or supplement and (C) file with the Commission any such amendment or supplement; <I>provided</I>, <I>however</I>, that the Company
shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably
object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters
may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the
Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of its
intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration
of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s)
a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which
the Representative or counsel for the Underwriters shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts
to maintain the registration of the shares of Common Stock under the Exchange Act provided that such provision shall not prevent
a sale, merger or similar transaction involving the Company. The Company shall not deregister the shares of Common Stock under
the Exchange Act without the prior written consent of the Representative which consent shall not be unreasonably withheld and provided
that such provision shall not prevent a sale, merger or similar transaction involving the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Free
Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall
not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission
or retained by the Company under Rule 433; <I>provided</I>, <I>however</I>, that the Representative shall be deemed to have consented
to each Issuer General Use Free Writing Prospectus hereto and any &ldquo;road show that is a written communication&rdquo; within
the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees
that it will treat each such free writing prospectus consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer
free writing prospectus,&rdquo; as defined in Rule 433, and that it has complied and will comply with the applicable requirements
of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If
at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result
of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement
or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the
Company will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing
Prospectus to eliminate or correct such conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
to the Underwriters of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available
to the Representative and counsel for the Representative, without charge, signed copies of the Registration Statement as originally
filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated
or deemed to be incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also
deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and each amendment
thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished
to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
to the Underwriters of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to each
Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company
hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by
Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented)
as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events
Requiring Notice to the Representative</U>. The Company shall use its best efforts to cause the Registration Statement to remain
effective with a current prospectus for at least three years after the Applicable Time, and shall notify the Representative immediately
and confirm the notice in writing: (i) of the issuance by the Commission of any stop order or of the initiation, or the threatening,
of any proceeding for that purpose; (ii) of the issuance by any state securities commission of any proceedings for the suspension
of the qualification of the Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening,
of any proceeding for that purpose; (iii) of the mailing and delivery to the Commission for filing of any amendment or supplement
to the Registration Statement or Prospectus; (iv) of the receipt of any comments or request for any additional information from
the Commission; and (v) of the happening of any event during the period described in this Section 3.5 that, in the judgment of
the Company, makes any statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus
untrue or that requires the making of any changes in (a) the Registration Statement in order to make the statements therein not
misleading, or (b) in the Pricing Disclosure Package or the Prospectus in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop
order or suspend such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting
of such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Review
of Financial Statements.</U> For a period of three years after the date of this Agreement, the Company, at its expense, shall cause
its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information; provided that
such provision shall not prevent a sale, merger or similar transaction involving the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing</U>.
The Company shall use its best efforts to maintain the listing of the shares of Common Stock (including the shares of Common Stock
included in the Public Securities, the Warrant Shares and the Preferred Conversion Shares) on the Exchange for at least three years
from the date of this Agreement provided that such provision shall not prevent a sale, merger or similar transaction involving
the Company;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intentionally
Omitted</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">3.9</TD><TD STYLE="text-align: justify"><U>Reports to the Representative</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Periodic
Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish to the Representative
copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally
to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the
Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every
press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii)
a copy of each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company
under the Securities Act; (v) a copy of each report or other communication furnished to stockholders and (vi) such additional documents
and information with respect to the Company and the affairs of any future subsidiaries of the Company as the Representative may
from time to time reasonably request; <I>provided</I>, <I>however</I>, the Representative shall sign, if requested by the Company,
a Regulation FD compliant confidentiality agreement which is reasonably acceptable to the Representative and Representative Counsel
in connection with the Representative&rsquo;s receipt of such information. Documents filed with the Commission pursuant to its
EDGAR system or otherwise publicly filed or made available shall be deemed to have been delivered to the Representative pursuant
to this Section 3.9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Agent; Transfer Sheets</U>. For a period of three years after the date of this Agreement, the Company shall retain a transfer agent
and registrar acceptable to the Representative (the &ldquo;<B>Transfer Agent</B>&rdquo;) and for a period of one year after the
date of this Agreement shall furnish to the Representative at the Company&rsquo;s sole cost and expense such transfer sheets of
the Company&rsquo;s securities as the Representative may reasonably request, including the daily and monthly consolidated transfer
sheets of the Transfer Agent and DTC; provided that such provision shall not prevent a sale, merger or similar transaction involving
the Company. Continental Stock Transfer &amp; Trust Company is acceptable to the Representative to act as Transfer Agent for the
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trading
Reports</U>. For a period of one (1) year after the date of this Agreement, the Company shall provide to the Representative, at
the Company&rsquo;s expense, such reports published by Exchange relating to price trading of the Public Securities, as the Representative
shall reasonably request; provided that such provision shall not prevent a sale, merger or similar transaction involving the Company.</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.4&#9;<U>Warrant Agent</U>&#9;For
so long as the Warrants and the Option Warrants are outstanding, the Company shall retain a warrant agent reasonably acceptable
to the Representative (the &ldquo;<B>Warrant Agent</B>&rdquo;). Corporate Stock Transfer, Inc. is acceptable to the Representative
to act as Warrant Agent for the Warrants and the Option Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Expenses</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent
not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (i) all filing fees and communication expenses relating to the registration of the Public Securities
with the Commission; (ii) all Public Filing System filing fees associated with the review of the Offering by FINRA; (iii) all fees
and expenses relating to the listing of such Public Securities on the Exchange and such other stock exchanges as the Company and
the Representative together determine; (iv) all fees, expenses and disbursements relating to the registration, qualification or
exemption of the Public Securities under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions as the
Representative may reasonably designate; (v) all fees, expenses and disbursements relating to the registration, qualification or
exemption of the Public Securities under the securities laws of such foreign jurisdictions as the Representative may reasonably
designate; (vi) the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting
Agreement, the Warrant Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&rsquo;
Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments,
supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary;
(vii) the costs of preparing, printing and delivering certificates representing the Public Securities; (viii) filing fees related
to the Certificate of Designation and fees and expenses of the transfer agent for the shares of Common Stock and Preferred Stock
and the Warrant Agent for the Warrants and Option Warrants; (ix) stock transfer and/or stamp taxes, if any, payable upon the transfer
of securities from the Company to the Underwriters; (x) the fees and expenses of the Company&rsquo;s accountants; (xi) the fees
and expenses of the Company&rsquo;s legal counsel and other agents and representatives; (xii) the fees and expenses of the Underwriters&rsquo;
legal counsel not to exceed $100,000; (xiii) up to $25,000 associated with the Representative&rsquo;s use of IPREO&rsquo;s book-building,
prospectus tracking and compliance software for the Offering; (xiv) up to $25,000 of the Representative&rsquo;s actual accountable
marketing and &ldquo;road show&rdquo; expenses for the Offering.; and (xv) up to $5,000 for expenses for background checks incurred
by the Representative. The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing
Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the
application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement, an
earnings statement (which need not be certified by independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities
Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stabilization</U>.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected
to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Internal
Controls</U>. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that:
(i) transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for
assets; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv)
the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor
is acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA</U>.
The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i)
any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company's securities or (iii)
any beneficial owner of the Company's unregistered equity securities which were acquired during the 180 days immediately preceding
the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in the
Offering (as determined in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in
a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering
and the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Lock-Up Agreements</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent
of the Representative, it will not for a period of ninety (90) days after the date of this Agreement (the &ldquo;<B>Lock-Up Period</B>&rdquo;),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company;
(ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company;
or (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii) or (iii) above is to be
settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The restrictions contained
in this Section 3.18 shall not apply to (i) the shares of Common Stock, Preferred Conversion Shares, Warrants or Option Warrants
to be sold hereunder or issuance of common stock upon conversion or exercise of any of the foregoing, (ii) the issuance by the
Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on
the date hereof, which is disclosed in the Registration Statement, Pricing Disclosure Package and Prospectus, or pursuant to the
exercise of the Warrants or the conversion of the Preferred Stock, (iii) the issuance by the Company of stock options or other
awards under any equity compensation plan of the Company, or (iv) the issuance of securities in connection with a business acquisition,
joint venture or partnership (so long as the purpose of such issuance is not solely for capital raising).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Blue
Sky Qualifications</U>. The Company shall use its best efforts, in cooperation with the Underwriters, if necessary, to qualify
the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Representative may designate with the consent of the Company and to maintain such qualifications in effect so
long as required to complete the distribution of the Public Securities; <I>provided</I>, <I>however</I>, that the Company shall
not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction
in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reporting
Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities as may be required under
Rule 463 under the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Press
Releases</U>. Prior to the 41<SUP>st</SUP> day following the Closing Date, the Company shall not issue any press release or other
communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise,
or earnings, business affairs or business prospects (except for routine communications in the ordinary course of business and of
which the Representative is notified), without the prior written consent of the Representative, which consent shall not be unreasonably
withheld, unless in the judgment of the Company and its counsel, and after notification to the Representative, such press release
or communication is required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley</U>.
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company shall at all
times comply with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Variable
Rate Transactions</U>. From the date hereof until 12 months following the date hereof, the Company shall be prohibited from effecting
or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock
Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. For the purposes hereof, &ldquo;<B>Variable
Rate Transaction</B>&rdquo; means a transaction in which the Company (i) issues or sells any debt or equity securities that are
convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A)
at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices
of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion,
exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity
security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company
as currently carried on and as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the
market for the Common Stock or (ii) enters into any agreement, including, but not limited to, an equity line of credit, whereby
the Company may issue securities at a future determined price that varies with the market per the terms of such agreement; provided
however that the foregoing does not apply to any existing agreements (including the Company&rsquo;s agreement with Cedars-Sinai
Medical Center) or outstanding securities on the date hereof and the Company shall not be prohibited under the foregoing from issuing
securities under any at-market agreement existing on the date hereof. Any Underwriter shall be entitled to obtain injunctive relief
against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">4.</FONT></TD><TD STYLE="text-align: justify"><U>Conditions of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase
and pay for the Public Securities, as provided herein, shall be subject to (i) the continuing accuracy of the representations and
warranties of the Company as of the date hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the
accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company
of its obligations hereunder; and (iv) the following conditions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1</TD><TD STYLE="text-align: justify"><U>Regulatory Matters</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Commission
Actions; Required Filings</U>. The Registration Statement has become effective not later than 5:00 p.m., Eastern time, on the date
of this Agreement or such later date and time as shall be consented to in writing by you. At each of the Closing Date and any Option
Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto
shall have been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the
Prospectus shall have been issued and no proceedings for any of those purposes shall have been instituted or are pending or, to
the Company&rsquo;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission
for additional information. The prospectus containing the Rule 430A Information shall have been filed with the Commission in the
manner and within the time frame required by Rule 424(b) under the Securities Act Regulations (without reliance on Rule 424(b)(8))
or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission
in accordance with the requirements of Rule 430A under the Securities Act Regulations. the Public Securities. At the time of such
filing, the Company met the requirements of Form S-1 under the Securities Act. The Registration Statement meets the requirements
set forth in Rule 415(a)(1)(iii) under the Securities Act with respect to the Warrant Shares and the Preferred Conversion Shares
and complies with said Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount
of compensation allowable or payable to the Underwriters as described in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange<B>&nbsp;</B>Stock
Market Clearance</U>. On or before the Closing Date, the shares of Common Stock included in the Public Securities, the Preferred
Conversion Shares and the Warrant Shares shall have been approved for listing on the Exchange, subject to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.2</TD><TD STYLE="text-align: justify"><U>Company Counsel Matters</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion and negative assurance
letter of Gracin &amp; Marlow, LLP, counsel to the Company, dated the Closing Date and addressed to the Representative, in form
and substance reasonably acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Special Intellectual Property Counsel for the Company</U>. On the Closing Date, the Representative shall have received the favorable
opinion letter of Morgan, Lewis &amp; Bockius LLP, as special intellectual property counsel for the Company, dated the Closing
Date and addressed to the Representative, in form and substance reasonably acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion of Special
Regulatory Counsel for the Company</U>. On the Closing Date, the Representative shall have received the favorable opinion letter
of Cooley LLP, as special regulatory counsel for the Company, dated the Closing Date and addressed to the Representative, in form
and substance reasonably acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.4 &nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Nevada Counse</U>l. On the Closing Date, the Representative shall have received the favorable opinion letter of Parsons Behle
 &amp; Latimer, as special Nevada counsel for the Company, dated the Closing Date and addressed to the Representative, in form
and substance reasonably acceptable to the Representative</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable
opinions and negative assurance letters of each counsel listed in Sections 4.2.1, 4.2.2, 4.2.3 and 4.2.4, dated the Option Closing
Date, addressed to the Representative and in form and substance reasonably satisfactory to the Representative, confirming as of
the Option Closing Date, the statements made by such counsels in their respective opinions delivered on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance</U>.
In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of the
United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of
other counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to
the extent they deem proper, on certificates or other written statements of officers of the Company and officers of departments
of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company; <I>provided</I>
that copies of any such statements or certificates shall be delivered to Representative Counsel if requested. The opinions of each
of Gracin &amp; Marlow, LLP, Morgan, Lewis &amp; Bockius LLP, Cooley LLP and Parsons, Behle &amp; Latimer and any opinion relied
upon by any of Gracin &amp; Marlow, LLP, Morgan, Lewis &amp; Bockius LLP, Cooley LLP and Parsons, Behle &amp; Latimer shall include
a statement to the effect that it may be relied upon by Representative Counsel in its opinion delivered to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
of Designation</U>. On or prior to the Closing Date, the Representative shall have received evidence of the filing and acceptance
of the Certificate of Designation of the Preferred Stock from the Secretary of State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.3</TD><TD STYLE="text-align: justify"><U>Comfort Letters</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cold
Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements
and information of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements
and certain financial information contained or incorporated or deemed incorporated by reference in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, addressed to the Representative and in form and substance satisfactory in all
respects to you and to the Auditor,<B>&nbsp;</B>dated as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down
Comfort Letter</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from
the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms
the statements made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date
not more than three (3) business days prior to the Closing Date or the Option Closing Date, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.4</TD><TD STYLE="text-align: justify"><U>Officers&rsquo; Certificates</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing
Date (if such date is other than the Closing Date), of its interim Chief Executive Officer who also serves as its Chief Financial
Officer stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any
Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto,
as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did
not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of
the Closing Date (or any Option Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as
of its date and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and the Prospectus
and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue
statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances in which they were made, not misleading, (ii) since the Applicable Time, no event has occurred which
should have been set forth in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus,
(iii) to the best of their knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such
date is other than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct
in all material respects (except for those representations and warranties which refer to facts existing at a specific date, which
shall be true and correct as of such date)and the Company has complied with all agreements and satisfied all conditions on its
part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than
the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial statements included
or incorporated by reference in the Pricing Disclosure Package, any material adverse change in the financial position or results
of operations of the Company, or any change or development that, singularly or in the aggregate, would involve a material adverse
change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations,
business, assets or prospects of the Company, except as set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&rsquo;s
Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate
of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively,
certifying: (i) that each of the Charter<B>&nbsp;</B>and Bylaws<B>&nbsp;</B>is true and complete, has not been modified and is
in full force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full
force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company
or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such
certificate shall be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Changes</U>. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been
no material adverse change or development involving a prospective material adverse change in the condition or prospects or the
business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the
Registration Statement and no change in the capital stock or debt of the Company, the Pricing Disclosure Package and the Prospectus;
(ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any director
or officer before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision,
ruling or finding may materially adversely affect the business, operations, prospects or financial condition or income of the Company,
except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iii) no stop order shall
have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission;
(iv) no action shall have been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued
by any Governmental Entity which would prevent the issuance or sale of the Public Securities or materially and adversely affect
or potentially materially and adversely affect the business or operations of the Company; (v) no injunction, restraining order
or order of any other nature by any federal or state court of competent jurisdiction shall have been issued which would prevent
the issuance or sale of the Public Securities or materially and adversely affect or potentially materially and adversely affect
the business or operations of the Company and (vi) the Registration Statement, the Pricing Disclosure Package and the Prospectus
and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance
with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the
Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package, the
Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Misstatement or Omission</U>. The Underwriters shall not have discovered and disclosed to the Company on or prior to the
Closing Date and any Option Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue
statement of a fact which, in the opinion of counsel for the Underwriters, is material or omits to state any fact which, in the
opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading,
or that the Registration Statement, Pricing Disclosure Package or the Prospectus or any amendment or supplement thereto contains
an untrue statement of fact which, in the opinion of such counsel, is material or omits to state any fact which, in the opinion
of such counsel, is material and is necessary in order to make the statements, in the light of the circumstances under which they
were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate
Proceedings</U>. All corporate proceedings and other legal matters incident to the authorization, form and validity of each of
this Agreement, the Public Securities, the Registration Statement, the Pricing Disclosure Package and the Prospectus and all other
legal matters relating to this Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory
in all material respects to counsel for the Underwriters, and the Company shall have furnished to such counsel all documents and
information that they may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.8</TD><TD STYLE="text-align: justify"><U>Delivery of Agreements</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-Up
Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies
of the Lock-Up Agreements from each of the persons listed in <U>Schedule 3</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Agreement</U>. As of the date hereof, the Company and the Warrant Agent shall have executed the Warrant Agreement and the Warrant
Agreement shall be in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Documents</U>. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall have been furnished with
such documents and opinions as they may require for the purpose of enabling Representative Counsel to deliver an opinion to the
Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the
conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities
as herein contemplated shall be satisfactory in form and substance to the Representative and Representative Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">5.</FONT></TD><TD STYLE="text-align: justify"><U>Indemnification</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1</TD><TD STYLE="text-align: justify"><U>Indemnification of the Underwriters.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and
each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates,
counsel and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act (collectively the &ldquo;<B>Underwriter Indemnified Parties</B>,&rdquo; and each an &ldquo;<B>Underwriter
Indemnified Party</B>&rdquo;), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited
to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced
or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and
the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them
may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws
of foreign countries (a &ldquo;<B>Claim</B>&rdquo;), (i) arising out of or based upon any untrue statement or alleged untrue statement
of a material fact contained in (A) the Registration Statement, the Pricing Disclosure Package, the Preliminary Prospectus, the
Prospectus or any Issuer Free Writing Prospectus (as from time to time each may be amended and supplemented); (B) any materials
or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering,
including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether in person or electronically);
or (C) any application or other document or written communication (in this Section 5, collectively called &ldquo;<B>application</B>&rdquo;)
executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the
Public Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, the
Exchange or any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to
be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading, unless such statement or omission was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information,
or (ii) otherwise arising in connection with or allegedly in connection with the Offering. The Company also agrees that it will
reimburse each Underwriter Indemnified Party for all fees and expenses (including but not limited to any and all legal or other
expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim
whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any
of the Underwriter Indemnified Parties and any third party, or otherwise) (collectively, the &ldquo;<B>Expenses</B>&rdquo;), and
further agrees wherever and whenever possible to advance payment of Expenses as they are incurred by an Underwriter Indemnified
Party in investigating, preparing, pursuing or defending any Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>.
If any action is brought against an indemnified party in respect of which indemnity may be sought against an indemnifying party
pursuant to Section 5.1.1 or 5.2, such indemnified party shall promptly notify the indemnifying party in writing of the institution
of such action and the indemnifying party shall assume the defense of such action, including the employment and fees of counsel
(subject to the approval of such indemnified party) and payment of actual expenses. Such indemnified party shall have the right
to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the indemnified
party unless (A) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (B)
the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or
other indemnified parties that are different from or in addition to those available to the indemnifying party, (C) a conflict or
potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified
party) or (D) the indemnifying party has not in fact employed counsel to assume the defense of such action or counsel satisfactory
to the indemnified party, in each case, within a reasonable time after receiving notice of the commencement of the action; in each
of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party
or parties.&nbsp; It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate
firm admitted to practice in such jurisdiction (plus local counsel) at any one time for all such indemnified party or parties.&nbsp;
All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred.&nbsp;
An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without itswritten consent..
In addition, the indemnifying party shall not, without the prior written consent of the the indemnified party, settle, compromise
or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which
advancement, reimbursement, indemnification or contribution may be sought hereunder (whether or not such indemnified party is a
party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release of each indemnified
party, acceptable to such indemnified party, from all liabilities, expenses and claims arising out of such action for which indemnification
or contribution may be sought and (ii) does not include a statement as to or an admission of fault, culpability or a failure to
act, by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of the Company</U>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the
foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions,
or alleged untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure
Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity
with, the Underwriters&rsquo; Information. In case any action shall be brought against the Company or any other person so indemnified
based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment
or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter, such Underwriter
shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights
and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the Representative
of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person, if any,
who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection
with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package,
the Prospectus or any Issuer Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">5.3</TD><TD STYLE="text-align: justify"><U>Contribution</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold
harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect
thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to
the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect
thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand,
and the Underwriters, on the other, from the Offering of the Public Securities, or (ii) if the allocation provided by clause (i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred
to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect
to the statements or omissions that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as
any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds from the Offering
of the Public Securities purchased under this Agreement (before deducting expenses) received by the Company, as set forth in the
table on the cover page of the Prospectus, on the one hand, and the total underwriting discounts and commissions received by the
Underwriters with respect to the shares of the Common Stock purchased under this Agreement, as set forth in the table on the cover
page of the Prospectus, on the other hand. The relative fault shall be determined by reference to whether the untrue or alleged
untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by
the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable
if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were treated
as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or
action in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1,
any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such
action or claim. Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute
any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with
respect to the Offering of the Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another
party (&ldquo;contributing party&rdquo;), notify the contributing party of the commencement thereof, but the failure to so notify
the contributing party will not relieve it from any liability which it may have to any other party other than for contribution
hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party
or its representative of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate
therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be
liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party
seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution
without the written consent of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended
to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise
available. Each Underwriter&rsquo;s obligations to contribute pursuant to this Section 5.3 are several and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">6.</FONT></TD><TD STYLE="text-align: justify"><U>Default by an Underwriter</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
Not Exceeding 10% of Firm Securities or Option Securities</U>. If any Underwriter or Underwriters shall default in its or their
obligations to purchase the Firm Securities or the Option Securities, if the Over-allotment Option is exercised hereunder, and
if the number of the Firm Securities or Option Securities with respect to which such default relates does not exceed in the aggregate
10% of the number of Firm Securities or Option Securities that all Underwriters have agreed to purchase hereunder, then such Firm
Securities or Option Securities to which the default relates shall be purchased by the non-defaulting Underwriters in proportion
to their respective commitments hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
Exceeding 10% of Firm Securities or Option Securities</U>. In the event that the default addressed in Section 6.1 relates to more
than 10% of the Firm Securities or Option Securities, you may in your discretion arrange for yourself or for another party or parties
to purchase such Firm Securities or Option Securities to which such default relates on the terms contained herein. If, within one
(1) Business Day after such default relating to more than 10% of the Firm Securities or Option Securities, you do not arrange for
the purchase of such Firm Securities or Option Securities, then the Company shall be entitled to a further period of one (1) Business
Day within which to procure another party or parties satisfactory to you to purchase said Firm Securities or Option Securities
on such terms. In the event that neither you nor the Company arrange for the purchase of the Firm Securities or Option Securities
to which a default relates as provided in this Section 6, this Agreement will automatically be terminated by you or the Company
without liability on the part of the Company (except as provided in Sections 3.9 and 5 hereof) or the several Underwriters (except
as provided in Section 5 hereof); <I>provided</I>, <I>however</I>, that if such default occurs with respect to the Option Securities,
this Agreement will not terminate as to the Firm Securities; and <I>provided</I>, <I>further</I>, that nothing herein shall relieve
a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Postponement
of Closing Date</U>. In the event that the Firm Securities or Option Securities to which the default relates are to be purchased
by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have
the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5)
Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure
Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to
the Registration Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter
may thereby be made necessary. The term &ldquo;<B>Underwriter</B>&rdquo; as used in this Agreement shall include any party substituted
under this Section 6 with like effect as if it had originally been a party to this Agreement with respect to such shares of Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">7.</FONT></TD><TD STYLE="text-align: justify"><U>Additional Covenants</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
Composition and Board Designations</U>. The Company shall ensure that: (i) the qualifications of the persons serving as members
of the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and
with the listing rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company
seeks to have its Public Securities listed on another exchange or quoted on an automated quotation system, and (ii) if applicable,
at least one member of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo;
as such term is defined under Regulation S-K and the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prohibition
on Press Releases and Public Announcements</U>. The Company shall not issue press releases or engage in any other publicity, without
the Representative&rsquo;s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1<SUP>st</SUP>)
Business Day following the forty-fifth (45<SUP>th</SUP>) day after the Closing Date, other than normal and customary releases or
releases required under applicable laws or the NYSE American.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">8.</FONT></TD><TD STYLE="text-align: justify"><U>Effective Date of this Agreement and Termination Thereof</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date</U>. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered
counterparts of such signatures to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic
or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially
disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock
Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or
maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government
authority having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase in major hostilities;
or (iv) if a banking moratorium has been declared by a New York State or federal authority; or (v) if a moratorium on foreign exchange
trading has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall
have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious
act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery
of the Firm Securities or Option Securities; or (vii) if the Company is in material breach of any of its representations, warranties
or covenants hereunder; or (viii) if the Representative shall have become aware after the date hereof of such a material adverse
change in the conditions or prospects of the Company, or such adverse material change in general market conditions as in the Representative&rsquo;s
judgment would make it impracticable to proceed with the offering, sale and/or delivery of the Public Securities or to enforce
contracts made by the Underwriters for the sale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section
6.2 above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein
or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual
and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable (including the fees
and disbursements of Representative Counsel) up to $75,000 and upon demand the Company shall pay the full amount thereof to the
Representative on behalf of the Underwriters; <I>provided</I>, <I>however</I>, that such expense cap in no way limits or impairs
the indemnification and contribution provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival
of Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full
force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this
Agreement or any part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations,
Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any
investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">9.</FONT></TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered
or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be
deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">A.G.P./Alliance Global Partners<BR>
590 Madison Avenue, 36<SUP>th</SUP> Floor<BR>
New York, New York 10022<BR>
Attn: Mr. David Bocchi, Head of Investment Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No.: (212) 813-1047</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Zysman, Aharoni, Gayer and Sullivan &amp; Worcester LLP<BR>
1633 Broadway<BR>
New York, New York 10019<BR>
Attention: Oded Har-Even, Esq.<BR>
Fax No.: (212) 660-3000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Synthetic Biologics, Inc.<BR>
9605 Medical Center Drive, Suite 270<BR>
Rockville, Maryland 20850<BR>
Attention: Steven A. Shallcross, Chief Executive Officer<BR>
Fax No: [&nbsp;&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Gracin &amp; Marlow, LLP<BR>
The Chrysler Building<BR>
405 Lexington Avenue, 26<SUP>th</SUP> Floor<BR>
New York, New York 10174<BR>
Attention: Leslie Marlow, Esq.<BR>
Fax No: (212) 208-4657</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Research
Analyst Independence</U>. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments are
required to be independent from its investment banking division and are subject to certain regulations and internal policies, and
that such Underwriter&rsquo;s research analysts may hold views and make statements or investment recommendations and/or publish
research reports with respect to the Company and/or the offering that differ from the views of their investment banking division.
The Company acknowledges that each Underwriter is a full service securities firm and as such from time to time, subject to applicable
securities laws, rules and regulations, may effect transactions for its own account or the account of its customers and hold long
or short positions in debt or equity securities of the Company; <I>provided</I>, <I>however</I>, that nothing in this Section 9.2
shall relieve the Underwriter of any responsibility or liability it may otherwise bear in connection with activities in violation
of applicable securities laws, rules or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with
this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding
Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters,
the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors,
legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors
and assigns&rdquo; shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance with
the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced
in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York,
and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to
such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon
the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid,
addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal
and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such
action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating
to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the
extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out
of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution
in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same
agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission
shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver,
etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed
or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof
or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach,
non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance
or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[<I>Signature Page Follows</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that
purpose, whereupon this letter shall constitute a binding agreement between us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Steven A. Shallcross</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD><P STYLE="margin: 0">Steven A. Shallcross</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD><P STYLE="margin: 0">Interim Chief Executive</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Confirmed as of the date first written above<BR>
mentioned, on behalf of itself and as<BR>
Representative of the several Underwriters<BR>
named on <U>Schedule 1</U> hereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A.G.P./ALLIANCE GLOBAL PARTNERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid">/s/ Tom Higgins</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Tom Higgins</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Managing Director, IBK</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">Synthetic
Biologics, Inc. &ndash; Underwriting Agreement</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><U>SCHEDULE
1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Underwriter</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number&nbsp;of<BR> Class&nbsp;A&nbsp;Units</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number&nbsp;of<BR> Class&nbsp;B&nbsp;Units</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number&nbsp;of&nbsp;Option<BR> Shares&nbsp;to&nbsp;be<BR> Purchased&nbsp;if&nbsp;the<BR> Over-Allotment<BR> Option&nbsp;is&nbsp;Fully<BR> Exercised&nbsp;by&nbsp;the<BR> Representative</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number&nbsp;of Option<BR> Warrants
    to&nbsp;be<BR>
Purchased if&nbsp;the<BR> Over-Allotment<BR> Option&nbsp;is&nbsp;Fully<BR>
    Exercised&nbsp;by&nbsp;the<BR>     Representative</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">A.G.P./Alliance Global Partners</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">2,520,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">15,723</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">2,428,825</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">2,428,825</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">TOTAL</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,520,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">15,723</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,428,825</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,428,825</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch. 1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE 2-A&nbsp;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pricing Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Class A Units: 2,520,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Class B Units: 15,723</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Option Shares: 2,428,825</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Option Warrants: 2,428,825</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Public Offering Price per Class A Unit: $1.15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Public Offering Price per Class B Unit: $1,000.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Warrant Exercise Price: $1.38</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Discount per Class A Unit: $0.0805</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Discount per Class B Unit: $70.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Discount per Option Share: $0.0798</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Discount per Option Warrant: $0.0007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Proceeds to Company per Class A Unit (before expenses): $1.0695</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Proceeds to Company per Class B Unit (before expenses): $930.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Proceeds to Company per Option Share (before expenses): $1.0602</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Proceeds to Company per Option Warrant (before expenses): $0.0093</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company shall be credited by an amount equal to $105,000 at
Closing; which shall reduce the aggregate Underwriting Discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal"><U>SCHEDULE
2-B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Issuer Free Writing Prospectus filed on October 2, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch. 2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE 3</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">List of Lock-Up Parties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Steven A. Shallcross</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Joseph Sliman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jeffrey J. Kraws</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Scott L. Tarriff</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jeffrey Wolf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch. 3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>EXHIBIT A</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Lock-Up Agreement&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A.G.P./Alliance Global Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">590 Madison Avenue, 36<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As Representative (the &ldquo;<B><I>Representative</I></B>&rdquo;)
of the several Underwriters named in the Underwriting Agreement referenced below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that you and certain other firms (the &ldquo;<B><I>Underwriters</I></B>&rdquo;) propose to enter into an Underwriting Agreement
(the &ldquo;<B><I>Underwriting Agreement</I></B>&rdquo;) providing for the purchase by the Underwriters of securities (the &ldquo;<B><I>Securities</I></B>&rdquo;),
including Common Stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), of Synthetic Biologics, Inc.,
a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and that the Underwriters propose to reoffer the Securities to
the public (the &ldquo;<B><I>Offering</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration of the
execution of the Underwriting Agreement by the Underwriters, and for other good and valuable consideration, the undersigned hereby
irrevocably agrees that, without the prior written consent of the Representative, on behalf of the Underwriters, the undersigned
will not, directly or indirectly, (1) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction
or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the
future of) any Common Stock (including, without limitation, Common Stock that may be deemed to be beneficially owned by the undersigned
in accordance with the rules and regulations of the Securities and Exchange Commission and Common Stock that may be issued upon
exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for Common Stock, (2) enter
into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or
risks of ownership of Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery
of Common Stock or other securities, in cash or otherwise, (3) except as provided for below, make any demand for or exercise any
right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any
Common Stock or securities convertible into or exercisable or exchangeable for Common Stock or any other securities of the Company,
or (4) publicly disclose the intention to do any of the foregoing for a period commencing on the date hereof and ending on the
90th day after the closing of the Offering (such 90-day period, the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing paragraph
shall not apply to (a) transactions relating to Common Stock or other securities acquired in the open market after the completion
of the Offering, <I>provided</I> that no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended (the <B><I>&ldquo;Exchange
Act&rdquo;</I></B>), shall be required or shall be voluntarily made in connection with such transfers; (b)&nbsp;bona fide gifts,
sales or other dispositions of shares of any class of the Company&rsquo;s capital stock or any security convertible into Common
Stock, in each case that are made exclusively between and among the undersigned or members of the undersigned&rsquo;s family, or
affiliates of the undersigned, including its partners (if a partnership) or members (if a limited liability company); (c) any transfer
of Common Stock or any security convertible into Common Stock by will or intestate succession upon the death of the undersigned;
(d)&nbsp;transfer of Common Stock or any security convertible into Common Stock to an immediate family member (for purposes of
this Lock-Up Letter Agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage or adoption, not more
remote than first cousin) or any trust, limited partnership, limited liability company or other entity for the direct or indirect
benefit of the undersigned or any immediate family member of the undersigned; <I>provided </I>that, in the case of clauses (b)-
(d)&nbsp;above, it shall be a condition to any such transfer that (i)&nbsp;the transferee/donee agrees to be bound by the terms
of this Lock-Up Letter Agreement (including, without limitation, the restrictions set forth in the preceding sentence) to the same
extent as if the transferee/donee were a party hereto, (ii)&nbsp;each party (donor, donee, transferor or transferee) shall not
be required by law (including without limitation the disclosure requirements of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;), and the Exchange Act) to make, and shall agree to not voluntarily make, any filing or public announcement
of the transfer or disposition prior to the expiration of the 90-day period referred to above, and (iii)&nbsp;the undersigned notifies
the Representative at least two business days prior to the proposed transfer or disposition; (e) the transfer of Common Stock to
the Company to satisfy withholding obligations for any equity award granted pursuant to the terms of the Company&rsquo;s stock
option/incentive plans, such as upon exercise, vesting, lapse of substantial risk of forfeiture, or other similar taxable event,
in each case on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis (which, for the avoidance of doubt shall not include
 &ldquo;cashless&rdquo; exercise programs involving a broker or other third party), <I>provided</I> that as a condition of any transfer
pursuant to this clause (e), that if the undersigned is required to file a report under Section 16(a) of the Exchange Act, reporting
a reduction in beneficial ownership of Common Stock or any securities convertible into or exercisable or exchangeable for Common
Stock during the Lock-Up Period, the undersigned shall include a statement in such report, and if applicable an appropriate disposition
transaction code, to the effect that such transfer is being made as a stock delivery or forfeiture in connection with a net value
exercise, or as a forfeiture or sale of shares solely to cover required tax withholding, as the case may be; (f)&nbsp;transfers
of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to a bona fide third
party tender offer made to all holders of the Common Stock, merger, consolidation or other similar transaction involving a change
of control (as defined below) of the Company, including voting in favor of any such transaction or taking any other action in connection
with such transaction, <I>provided</I> that in the event that such merger, tender offer or other transaction is not completed,
the Common Stock and any security convertible into or exercisable or exchangeable for Common Stock shall remain subject to the
restrictions set forth herein; (g)&nbsp;the exercise of warrants or the exercise of stock options granted pursuant to the Company&rsquo;s
stock option/incentive plans or otherwise outstanding on the date hereof; <I>provided</I>, that the restrictions shall apply to
Common Stock issued upon such exercise or conversion; (h) the establishment of any contract, instruction or plan that satisfies
all of the requirements of Rule 10b5-1 (a &ldquo;<B><I>Rule 10b5-1 Plan</I></B>&rdquo;) under the Exchange Act; <I>provided</I>,
<I>however</I>, that no sales of Common Stock or securities convertible into, or exchangeable or exercisable for, Common Stock,
shall be made pursuant to a Rule 10b5-1 Plan prior to the expiration of the Lock-Up Period; <I>provided further</I>, that the Company
is not required to report the establishment of such Rule 10b5-1 Plan in any public report or filing with the Commission under the
Exchange Act during the lock-up period and does not otherwise voluntarily effect any such public filing or report regarding such
Rule 10b5-1 Plan; and (i) any demands or requests for, exercise any right with respect to, or take any action in preparation of,
the registration by the Company under the Act of the undersigned&rsquo;s Common Stock, provided that no transfer of the undersigned&rsquo;s
Common Stock registered pursuant to the exercise of any such right and no registration statement shall be filed under the Act with
respect to any of the undersigned&rsquo;s Common Stock during the Lock-Up Period. For purposes of clause (f) above, &ldquo;change
of control&rdquo; shall mean the consummation of any bona fide third party tender offer, merger, purchase, consolidation or other
similar transaction the result of which is that any &ldquo;person&rdquo; (as defined in Section 13(d)(3) of the Exchange Act),
or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total
voting power of the voting stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer
of the undersigned&rsquo;s securities subject to this Lock-Up Letter Agreement except in compliance with this Lock-Up Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is understood that,
if the Company notifies the Underwriters that it does not intend to proceed with the Offering, if the Underwriting Agreement does
not become effective, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Securities, the undersigned will be released from its obligations under
this Lock-Up Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the Company and the Underwriters will proceed with the Offering in reliance on this Lock-Up Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Whether or not the Offering
actually occurs depends on a number of factors, including market conditions. Any Offering will only be made pursuant to an Underwriting
Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Lock-Up Letter Agreement
shall automatically terminate upon the earliest to occur, if any, of (1) the termination of the Underwriting Agreement before the
sale of any Securities to the Underwriters or (2) December 17, 2018, in the event that the Underwriting Agreement has not been
executed by that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><I>[Signature page
follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The undersigned hereby represents
and warrants that the undersigned has full power and authority to enter into this Lock-Up Letter Agreement and that, upon request,
the undersigned will execute any additional documents necessary in connection with the enforcement hereof. Any obligations of the
undersigned shall be binding upon the heirs, personal representative, successors and assigns of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Name - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Signature)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Name of Signatory, in the case of entities - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Title of Signatory, in the case of entities - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>tv504760_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center; font-size: 10pt"><FONT STYLE="background-color: white"><IMG SRC="tv504760_ex3-1img2.jpg" ALT=""></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="background-color: white"></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="7" STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B><IMG SRC="tv504760_ex3-1img1.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-size: 10pt"><B>BARBARA K. CEGAVSKE</B></FONT></TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 19%">&nbsp;</TD>
    <TD STYLE="width: 21%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Secretary of State</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>202 North Carson Street</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed in the office of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Barbara K Cegavske</P></TD>
    <TD ROWSPAN="2" STYLE="border: Black 1pt solid"><FONT STYLE="font-size: 10pt">Document Number </FONT><BR>
<FONT STYLE="font-size: 10pt"><B>20180444980-40</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Carson City, Nevada 89701-4201</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>(775) 584-5708</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Barbara K. Cegavske </FONT><BR>
<FONT STYLE="font-size: 10pt">Secretary of State</FONT></TD>
    <TD ROWSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Filing&nbsp;&nbsp;Date and Time </FONT><BR>
<FONT STYLE="font-size: 10pt"><B>10/11/2018 9:58 AM</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Website: www.nvsos.gov</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">State of Nevada</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">Entity Number</FONT><BR>
<FONT STYLE="font-size: 10pt"><B>E0776232008-6</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 18pt"><B>Certificate of Designation</B></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">(PURSUANT TO NRS 78.1955)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>USE BLACK INK ONLY - DO NOT HIGHLIGHT</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>ABOVE SPACE 13 FOR OFFICE USE ONLY</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Certificate of Designation For</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Nevada Profit Corporations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Pursuant to NRS 78.1955)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0">&nbsp;</TD>
    <TD STYLE="width: 0.2in">1.</TD>
    <TD>Name of corporation:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologies, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;By resolution of
the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding
the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned, a duly authorized officer of Synthetic Biologics,
Inc., a corporation organized and existing under the laws of the State of Nevada (the &ldquo;Company&rdquo;), in accordance with
the Company&rsquo;s Articles of Incorporation (the &ldquo;Articles&rdquo;) and the provisions of Sections 78.195 and 78.1955 of
the Nevada Revised Statutes (the &ldquo;NRS&rdquo;), does hereby certify that the following resolution was duly approved and adopted
by the Board of Directors of the Company (the &ldquo;Board&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 1%">3.</TD><TD STYLE="width: 99%">Effective date of filing: (optional)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">(must not be later than 90 days after the certificate is filed)</FONT></TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1%">4.</TD><TD STYLE="width: 99%">Signature: (required)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>X &nbsp;&nbsp;</B><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    <FONT STYLE="background-color: white">Steven A. Shallcross</FONT></FONT></FONT></TD>
    <TD STYLE="width: 50%"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Signature of Officer</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Filing Fee: $175.00</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT:</B> Failure to Include any of the above information
and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt"><B>Nevada Secretary of State Stock Designation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><I>This form must be accompanied by appropriate fees.</I></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>Revised: 1-5-15</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">SYNTHETIC
BIOLOGICS, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">CERTIFICATE
OF DESIGNATION OF PREFERENCES,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">RIGHTS
AND LIMITATIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">SERIES
B CONVERTIBLE PREFERRED STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">PURSUANT
TO SECTION 78.1955 OF THE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">NEVADA
GENERAL CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
undersigned, Steven A. Shallcross, does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;He
is the Interim Chief Executive Officer and Chief Financial Officer of Synthetic Biologics, Inc., a Nevada corporation (the &ldquo;Corporation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is authorized to issue 10,000,000 shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following resolutions were duly adopted by the board of directors of the Corporation (the &ldquo;Board of Directors&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>FURTHER
RESOLVED</B>, that the Authorized Officer be, and hereby is, authorized, empowered and directed to file with the Secretary of State
of the State of Nevada a Certificate of Designation for Series B Convertible Preferred Stock (the &ldquo;<U>Certificate of Designation</U>&rdquo;),
in the form approved by the interim Chief Executive Officer with the advice of counsel with rights, preferences and designations
as set forth on <U>Exhibit A</U> annexed hereto, with such changes as management upon the advice of counsel may deem appropriate
or necessary; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">TERMS
OF PREFERRED STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section 1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><U>Definitions</U>.
For the purposes hereof, the following terms shall have the following meanings:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Affiliate&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Alternate
Consideration&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Beneficial
Ownership Limitation&rdquo; shall have the meaning set forth in Section 6(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Business
Day&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Buy-In&rdquo;
shall have the meaning set forth in Section 6(c)(iv).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Commission&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Common
Stock&rdquo; means the Corporation&rsquo;s common stock, par value $0.001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Common
Stock Equivalents&rdquo; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Conversion
Amount&rdquo; means the sum of the Stated Value at issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Conversion
Date&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Conversion
Price&rdquo; shall have the meaning set forth in Section 6(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Conversion
Shares&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance
with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Exchange
Act&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Fundamental
Transaction&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;GAAP&rdquo;
means United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Holder&rdquo;
shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Liquidation&rdquo;
shall have the meaning set forth in Section 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;New
York Courts&rdquo; shall have the meaning set forth in Section 8(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Notice
of Conversion&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Original
Issue Date&rdquo; means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers
of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Person&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Preferred
Stock&rdquo; shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Representative&rdquo;
means A.G.P./Alliance Global Partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Securities
Act&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Share
Delivery Date&rdquo; shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Stated
Value&rdquo; shall have the meaning set forth in Section 2, as the same may be increased pursuant to Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Subsidiary&rdquo;
means any subsidiary of the Corporation and shall, where applicable, also include any direct or indirect subsidiary of the Corporation
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Successor
Entity&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Trading
Day&rdquo; means a day on which the principal Trading Market is open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Trading
Market&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE American or the
New York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Transfer
Agent&rdquo; means Corporate Stock Transfer, Inc., the current transfer agent of the Corporation, with a mailing address of 13200
Cherry Creek South Drive, Suite 430, Denver, Colorado 80209 and an email address of cbell@corporatestock.com and any successor
transfer agent of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&ldquo;Underwriting
Agreement&rdquo; means the underwriting agreement, dated as of October 10, 2018, by and between the Corporation and the Representative
as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with
its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Designation, Amount
and Par Value</U>. The series of preferred stock shall be designated as the Series B Convertible Preferred Stock (the &ldquo;Preferred
Stock&rdquo;) and the number of shares so designated shall be up to Fifteen Thousand One Hundred and Two (15,102) (which shall
not be subject to increase without the written consent of a majority of the holders of the Preferred Stock (each, a &ldquo;Holder&rdquo;
and collectively, the &ldquo;Holders&rdquo;)). Each share of Preferred Stock shall have a par value of $0.001 per share and a stated
value equal to $1,000 (the &ldquo;Stated Value&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Dividends</U>. Except
for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders shall be entitled to receive,
and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis, without
regard to conversion limitations herein) to and in the same form as dividends actually paid on shares of the Common Stock when,
as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares of Preferred Stock.
The Corporation shall not pay any dividends on the Common Stock unless the Corporation simultaneously complies with this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Voting Rights</U>.
Except as otherwise provided herein or as otherwise required by law, the Preferred Stock shall have no voting rights. However,
as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders
of a majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences or
rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b) amend its certificate of incorporation
or other charter documents in any manner that adversely affects any rights of the Holders, (c) increase the number of authorized
shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Liquidation</U>.
Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &ldquo;Liquidation&rdquo;),
the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that
a holder of Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion
limitations hereunder) to Common Stock which amounts shall be paid <I>pari passu</I> with all holders of Common Stock. The Corporation
shall mail written notice of any such Liquidation, not less than 45 days prior to the payment date stated therein, to each Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section 6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><U>Conversion</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Conversions
at Option of Holder</U>. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the
Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations
set forth in Section 6(d)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders
shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <U>Annex A</U> (a &ldquo;Notice
of Conversion&rdquo;). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number
of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to
the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable
Holder delivers by facsimile such Notice of Conversion to the Corporation (such date, the &ldquo;Conversion Date&rdquo;). If no
Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to
the Corporation is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. The calculations and entries
set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. To effect conversions of
shares of Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing the shares of Preferred
Stock to the Corporation unless all of the shares of Preferred Stock represented thereby are so converted, in which case such Holder
shall deliver the certificate representing such shares of Preferred Stock promptly following the Conversion Date at issue. Shares
of Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled and shall not
be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Conversion
Price</U>. The conversion price for the Preferred Stock shall equal $1.15, subject to adjustment herein (the &ldquo;Conversion
Price&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Mechanics
of Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Delivery
of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;Share Delivery Date&rdquo;),
the Corporation shall deliver, or cause to be delivered, to the converting Holder (A) the number of Conversion Shares being acquired
upon the conversion of the Preferred Stock, which Conversion Shares shall be free of restrictive legends and trading restrictions
and (B) a bank check in the amount of accrued and unpaid dividends, if any. The Corporation shall use its best efforts to deliver
the Conversion Shares required to be delivered by the Corporation under this Section 6 electronically through the Depository Trust
Company (&ldquo;DTC&rdquo;) or another established clearing corporation performing similar functions. As used herein, &ldquo;Standard
Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Corporation&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Conversion. Notwithstanding
the foregoing, with respect to any Notice(s) of Conversion delivered by 12:00 pm (NY time) on the Original Issue Date, the Corporation
agrees to deliver the Conversion Shares subject to such notice(s) by 4:00 pm (NY time) on the Original Issue Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Failure
to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as
directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation
at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall
promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly
return to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Obligation
Absolute; Partial Liquidated Damages</U>. The Corporation&rsquo;s obligation to issue and deliver the Conversion Shares upon conversion
of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by
a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against
any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach
or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation
of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation
of the Corporation to such Holder in connection with the issuance of such Conversion Shares; provided, however, that such delivery
shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder. If the Corporation
fails to deliver to a Holder such Conversion Shares pursuant to Section 6(c)(i) by the Share Delivery Date applicable to such conversion,
the Corporation shall pay to such Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Stated Value
of Preferred Stock being converted, $10 per Trading Day for each Trading Day after the Share Delivery Date until such Conversion
Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a Holder&rsquo;s right to pursue actual damages
for the Corporation&rsquo;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have
the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages
pursuant to any other Section hereof or under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the
Holder, if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date
pursuant to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in
an open market transaction or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion
relating to such Share Delivery Date (a &ldquo;Buy-In&rdquo;), then the Corporation shall (A) pay in cash to such Holder (in addition
to any other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&rsquo;s total purchase
price (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number
of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale
price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)
at the option of such Holder, either reissue (if surrendered) the shares of Preferred Stock equal to the number of shares of Preferred
Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number
of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under
Section 6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a
Buy-In with respect to an attempted conversion of shares of Preferred Stock with respect to which the actual sale price of the
Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause
(A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide
the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the
Corporation, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive
relief with respect to the Corporation&rsquo;s failure to timely deliver Conversion Shares upon conversion of the shares of Preferred
Stock as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all times reserve and keep available out of its
authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock as herein
provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the
other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall be issuable (taking
into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of Preferred Stock.
The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly
issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Fractional
Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Conversion Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Transfer
Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Preferred Stock shall be made without charge to
any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion
Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved
in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares
of Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion Shares unless or until the Person
or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established
to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required
for same-day processing of any Notice of Conversion and all fees to the DTC (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Conversion Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Beneficial
Ownership Limitation</U>. Notwithstanding anything to the contrary herein, the Corporation shall not effect any conversion of the
Preferred Stock, and a Holder shall not have the right to convert any portion of the Preferred Stock, to the extent that, after
giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with such Holder&rsquo;s
Affiliates, and any Persons acting as a group together with such Holder or any of such Holder&rsquo;s Affiliates (such Persons,
 &ldquo;Attribution Parties&rdquo;)) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates
and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Preferred Stock with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon
(i) conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the
Corporation subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without
limitation, the Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution Parties. Except as set
forth in the preceding sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained
in this Section 6(d) applies, the determination of whether the Preferred Stock is convertible (in relation to other securities
owned by such Holder together with any Affiliates and Attribution Parties) and of how many shares of Preferred Stock are convertible
shall be in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s
determination of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder together
with any Affiliates and Attribution Parties) and how many shares of the Preferred Stock are convertible, in each case subject to
the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the
Corporation each time it delivers a Notice of Conversion that such conversion will not violate the restrictions set forth in this
paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such representation. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. For purposes of this Section 6(d), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the
following: (i) the Corporation&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (ii)
a more recent public announcement by the Corporation or (iii) a more recent written notice by the Corporation or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written or oral request (which may be via email) of a
Holder, the Corporation shall within two Trading Days confirm orally and in writing to such Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates or
Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial
Ownership Limitation&rdquo; shall be 4.99% (except as otherwise specified or provided for to the Corporation prior to the issuance
of any Preferred Stock or in the Beneficial Ownership Limitation Adjustment Notice (as defined below)) of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion
of Preferred Stock held by the applicable Holder. A Holder may increase or decrease the Beneficial Ownership Limitation applicable
to its Preferred Stock by providing written notice to the Corporation (which notice may not be waived) in the form attached hereto
as Annex B (the &ldquo;Beneficial Ownership Limitation Adjustment Notice&rdquo;); provided that the Beneficial Ownership Limitation
in no event may exceed 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon conversion of this Preferred Stock held by the Holder and the provisions of this Section 6(d) shall
continue to apply; and provided further that a Holder who fails to specify a Beneficial Ownership Limitation in a Beneficial Ownership
Limitation Adjustment Notice or who specifies a Beneficial Ownership Limitation in a Beneficial Ownership Limitation Adjustment
Notice in excess of 9.99% shall be deemed to have specified a Beneficial Ownership Limitation of 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion
of Preferred Stock held by the applicable Holder. Any such increase in the Beneficial Ownership Limitation will not be effective
until the 61st day after such Beneficial Ownership Limitation Adjustment Notice is delivered to the Corporation and shall only
apply to such Holder and no other Holder. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 6(d) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary
or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section 7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><U>Certain Adjustments</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Stock
Dividends and Stock Splits</U>. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common
Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion
of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number
of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the
Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section
7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder
had held the number of shares of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Preferred Stock (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Pro
Rata Distributions</U>. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by
way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
 &ldquo;Distribution&rdquo;), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete conversion of this Preferred Stock (without regard to any
limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder&rsquo;s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the
Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of
Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for
the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Fundamental
Transaction</U>. If, at any time while any shares of Preferred Stock are outstanding, (i) the Corporation, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the
Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the
holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby
such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a &ldquo;Fundamental Transaction&rdquo;), then, upon
any subsequent conversion of the Preferred Stock by the Holder thereof, the Holder shall receive, for each Conversion Share that
would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard
to any limitation in Section 6(d) on the conversion of the Preferred Stock), the number of shares of common stock (as applicable)
of the successor or acquiring corporation or the number of shares of Common Stock of the Corporation (as applicable), if it is
the surviving corporation, and all additional securities (equity or debt), cash, property or other consideration (all such additional
consideration, the &ldquo;Alternate Consideration&rdquo;), receivable as a result of such Fundamental Transaction by a holder of
the number of shares of Common Stock for which such Holder&rsquo;s Preferred Stock is convertible immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 6(d) on the conversion of the Preferred Stock). For purposes of any such
conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are entitled to elect the
proportion of securities, cash, property or other consideration to be received by holders of Common Stock in a Fundamental Transaction,
then each Holder of Preferred Stock shall be given the same choice as to the proportion of securities, cash, property or other
consideration such Holder is entitled to receive upon any conversion of such Holder&rsquo;s shares of Preferred Stock following
such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation
or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation in respect of a new series of preferred
stock of the successor or acquiring corporation, or the Corporation, if it is the surviving corporation, setting forth the same
rights, preferences, privileges and other terms contained in this Certificate of Designation in respect of the Preferred Stock,
including, without limitation, the provisions contained in this Section 7(d) and evidencing, among other things, the Holders&rsquo;
right to convert such new preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental
Transaction in which the Corporation is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations
of the Corporation under this Certificate of Designation in accordance with the provisions of this Section 7(d) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of a Holder of Preferred Stock, deliver to such Holder in exchange
for such Holder&rsquo;s Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to the Preferred Stock which is convertible for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of the
Preferred Stock (without regard to any limitations on the conversion of the Preferred Stock) prior to such Fundamental Transaction,
and with a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such conversion price being for the purpose of protecting the economic value
of the Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder(s) thereof. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate
of Designation referring to the &ldquo;Corporation&rdquo; shall refer instead to the Successor Entity), and may exercise every
right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation
with the same effect as if such Successor Entity had been named as the Corporation herein. For the avoidance of doubt, if, at any
time while any shares of Preferred Stock are outstanding, a Fundamental Transaction occurs, pursuant to the terms of this Section
7(d), a Holder of Preferred Stock shall not be entitled to receive any consideration in such Fundamental Transaction in respect
of such Holder&rsquo;s shares of Preferred Stock, except as provided for in this Certificate of Designation (or any new Certificate
of Designation in respect of a new series of preferred stock issued to the Holders of Preferred Stock as contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Calculations</U>.
All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white">Notice
to the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation
shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief
statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Notice
to Allow Conversion by Holder</U>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any
sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common
Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be
filed at each office or agency maintained for the purpose of conversion of this Preferred Stock, and shall cause to be delivered
to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least fifteen (15) calendar days
prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date
as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein
or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the
extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Corporation
or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to convert the Conversion Amount of this Preferred Stock (or any part hereof) during
the 15-day period commencing on the date of such notice through the effective date of the event triggering such notice except as
may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section 8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><U>Miscellaneous</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Conversion, shall be in writing and delivered personally, by facsimile, email address or sent by a nationally recognized
overnight courier service, addressed to the Corporation at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Synthetic Biologics,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">9605 Medical Center
Drive, Suite 270</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Rockville, Maryland
20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Attention: Chief
Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Facsimile: (301)
417-4367</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Email address:
<U>sshallcross@syntheticbiologics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">with a copy (which
shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Gracin &amp; Marlow,
LLP</FONT><BR>
<FONT STYLE="background-color: white">405 Lexington Avenue, 26th Floor</FONT><BR>
<FONT STYLE="background-color: white">New York, New York 10174</FONT><BR>
<FONT STYLE="background-color: white">Attention: Leslie Marlow</FONT><BR>
<FONT STYLE="background-color: white">Email address: <U>lmarlow@gracinmarlow.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">Facsimile: (212)
208-4657</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">or
such other facsimile number or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance
with this Section 8. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall
be in writing and delivered personally, by facsimile, by email attachment or sent by a nationally recognized overnight courier
service addressed to each Holder at the facsimile number, email address or address of such Holder appearing on the books of the
Corporation, or if no such facsimile number, email address or address appears on the books of the Corporation, at the principal
place of business of such Holder. Any notice or other communication or deliveries hereunder shall be deemed given and effective
on the earliest of (i) the time of transmission, if such notice or communication is delivered via facsimile or email attachment
at the facsimile number or email address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the
next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or email attachment
at the facsimile number or email address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the Person to whom such notice is required to be given. Notwithstanding
any other provision of this Certificate of Designation, where this Certificate of Designation provides for notice of any event
to a Holder, if the Preferred Stock is held in global form by DTC (or any successor depositary), such notice may be delivered via
DTC (or such successor depositary) pursuant to the procedures of DTC (or such successor depositary).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Absolute
Obligation</U>. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the
obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages and accrued dividends, as applicable,
on the shares of Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Lost
or Mutilated Preferred Stock Certificate</U>. If a Holder&rsquo;s Preferred Stock certificate shall be mutilated, lost, stolen
or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated
certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of
Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of
such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation
shall be governed by and construed and enforced in accordance with the internal laws of the State of Nevada, without regard to
the principles of conflict of laws thereof. Each of the Corporation and each Holder agrees that all legal proceedings concerning
the interpretation, enforcement and defense of the transactions contemplated by this Certificate of Designation (whether brought
against the Corporation, a Holder or any of their respective Affiliates, directors, officers, shareholders, employees or agents)
shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;New York Courts&rdquo;).
Each of the Corporation and each Holder hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding.
Each of the Corporation and each Holder hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such Person at the address in effect for notices to it under this Certificate of Designation and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to
limit in any way any right to serve process in any other manner permitted by applicable law. Each of the Corporation and each Holder
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If the Corporation or any
Holder shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and expenses
incurred in the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Waiver</U>.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as
or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate
of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to
any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that Person (or
any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of
Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Severability</U>.
If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable
to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates
the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
rate of interest permitted under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Next
Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not
be deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white"><U>Status
of Converted or Redeemed Preferred Stock</U>. If any shares of Preferred Stock shall be converted, redeemed or reacquired by the
Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated
as Series B Convertible Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">*********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">RESOLVED,
FURTHER, that the executive chairman, the president or any vice-president, and the secretary or any assistant secretary, of the
Corporation be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences,
Rights and Limitations in accordance with the foregoing resolution and the provisions of Nevada law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">IN
WITNESS WHEREOF, the undersigned have executed this Certificate this 11th day of October, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">By:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ <FONT STYLE="background-color: white">Steven
    A. Shallcross</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Steven A. Shallcross &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Interim Chief Executive Officer and
    Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">ANNEX
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">NOTICE
OF CONVERSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">(TO
BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED STOCK)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
undersigned hereby elects to convert the number of shares of Series B Convertible Preferred Stock indicated below into shares of
common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), of Synthetic Biologics, Inc., a Nevada corporation (the
 &ldquo;Corporation&rdquo;), according to the conditions hereof, as of the date written below. If shares of Common Stock are to
be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Conversion calculations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; font-size: 10pt"><FONT STYLE="background-color: white">Date to Effect Conversion: </FONT></TD>
    <TD STYLE="width: 78%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; font-size: 10pt"><FONT STYLE="background-color: white">Number of shares of Preferred Stock owned prior to Conversion: </FONT></TD>
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; font-size: 10pt"><FONT STYLE="background-color: white">Number of shares of Preferred Stock to be Converted: </FONT></TD>
    <TD STYLE="width: 57%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="background-color: white">Stated Value of shares of Preferred Stock to be Converted: </FONT></TD>
    <TD STYLE="width: 53%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; font-size: 10pt"><FONT STYLE="background-color: white">Number of shares of Common Stock to be Issued: </FONT></TD>
    <TD STYLE="width: 59%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><FONT STYLE="background-color: white">Applicable Conversion Price: </FONT></TD>
    <TD STYLE="width: 75%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 10pt"><FONT STYLE="background-color: white">Number of shares of Preferred Stock subsequent to Conversion: </FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; font-size: 10pt"><FONT STYLE="background-color: white">Address for Delivery:</FONT></TD>
    <TD STYLE="width: 36%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; font-size: 10pt"><FONT STYLE="background-color: white">or</FONT></TD>
    <TD STYLE="width: 36%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; font-size: 10pt"><FONT STYLE="background-color: white">DWAC Instructions:</FONT></TD>
    <TD STYLE="width: 36%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="background-color: white">Broker no: </FONT></TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 55%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%"><FONT STYLE="background-color: white">Account no:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 54%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="background-color: white">[HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="background-color: white">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 59%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">ANNEX
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">BENEFICIAL
OWNERSHIP LIMITATION ADJUSTMENT NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white">(TO
BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO INCREASE OR DECREASE THE BENEFICIAL OWNERSHIP LIMITATION APPLICABLE TO SUCH HOLDER&rsquo;S
PREFERRED STOCK)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">By
checking the box below, the undersigned hereby irrevocably elects to waive the 4.99% Beneficial Ownership Limitation, as designated
by the undersigned&rsquo;s election below, applicable to the undersigned&rsquo;s beneficial ownership of Series B Convertible Preferred
Stock of Synthetic Biologics, Inc., a Nevada corporation, as such Beneficial Ownership Limitation is defined under Section 6(d)
of the Certificate of Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">The undersigned hereby elects to waive the Beneficial Ownership Limitation applicable
to the undersigned&rsquo;s beneficial ownership of Series B Convertible Preferred Stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
Beneficial Ownership Limitation applicable to the undersigned&rsquo;s Series B Convertible Preferred Stock (effective as of the
date that is 61 days following the date of this Beneficial Ownership Limitation Adjustment Notice) shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="background-color: white">______________________%
(may not be more than 9.99%)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">* Notice: Failure to specify
a Beneficial Ownership Limitation percentage above will result in the undersigned&rsquo;s being deemed to have specified a Beneficial
Ownership Limitation of 9.99%. Specifying a Beneficial Ownership Limitation percentage in excess of 9.99% will result in the undersigned&rsquo;s
being deemed to have specified a Beneficial Ownership Limitation of 9.99%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The undersigned understands
and agrees that, as a result of this waiver, the Beneficial Ownership Limitation applicable to the Series B Convertible Preferred
Stock beneficially owned by the undersigned shall be (i) the percentage specified by the undersigned above or (ii) 9.99% and, in
each case, the provisions of Section 6(d) of the Certificate of Designation shall continue to apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The undersigned understands
and agrees that by waiving the Beneficial Ownership Limitation, the undersigned may become subject to the reporting requirements
and liability provisions of Sections 13 and 16 of the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="background-color: white">[HOLDER]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 56%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 38%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>tv504760_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="float: left; width: 50%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><IMG SRC="tv504760_ex3-2img1.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>BARBARA K. CEGAVSKE</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Secretary of State</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>202 North Carson Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Carson City, Nevada 89701-4201</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(775) 884-5708</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Website: <U STYLE="text-decoration: none">www.nvsos.gov</U></B></P></TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Amendment
    to<BR>
    Certificate of Designation<BR>
    Before Issuance of Class or Series</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PURSUANT
    TO NRS 78.1955)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt">&nbsp;</P>

</div>
<DIV STYLE="float: right; width: 47%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0.25in">&nbsp;<IMG SRC="tv504760_ex3-2img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="6" STYLE="width: 50%; border: Black 1pt solid; padding-left: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Filed in the office of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ Barbara K. Cegavske</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Barbara K. Cegavske</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Secretary of State</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">State of Nevada</P></TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Document Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; border-right: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20180446395-92</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; border-right: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filling Date and Time</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; border-right: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10/12/2018 8:30 AM</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; border-right: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; border-right: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>E0776232008-6</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt"></P>

</div>
<DIV STYLE="clear:both;"></div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE BUCK INK ONLY &bull; DO NOT HIGHLIGHT</B></FONT></TD>
    <TD STYLE="width: 56%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOVE SPACE 18 FOR OFFICE USE ONLY</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pt; text-align: center"><B><U>Certificate of Amendment to Certificate
of Designation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pt; text-align: center"><B><U>For Nevada Profit Corporations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pt; text-align: center"><B>(Pursuant to NRS 78.1955 - Before
Issuance of Class or Series)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19pt; text-align: justify; text-indent: -0.25in">1. Name of
corporation:&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Synthetic Biologics, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">2. The original class or series of
stock set forth:&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B Convertible Preferred Stock</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">3. By a resolution of the board of
directors the original class or series is amended as follows:&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">Section 2 is hereby amended to read
        as follows:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 2. Designation, Amount and Par Value. The series of preferred
        stock shall be designated as the Series B Convertible Preferred Stock (the &ldquo;Preferred Stock&rdquo;) and the number of shares
        so designated shall be up to Fifteen Thousand Seven Hundred Twenty Three (15,723) (which shall not be subject to increase without
        the written consent of a majority of the holders of the Preferred Stock (each, a &ldquo;Holder&rdquo; and collectively, the &ldquo;Holders&rdquo;)).
        Each share of Preferred Stock shall have a par value of $0,001 per share and a stated value equal to $1,000 (the &ldquo;Stated
        Value&rdquo;).</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">4. As of the date of this certificate
no shares of the class or series of stock have been Issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. Effective date of filing: (optional)</FONT></TD>
    <TD STYLE="width: 75%; border: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(must not be later than 90 days after the certificate is filed)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 199pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">6. Signature: (required)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X</B></FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid">/s/ Steven A. Shallcross</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature of Officer</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><B>Filing Fee: $175.00</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><B>IMPORTANT: </B>Failure to Include
any of the above information and submit with the proper fees may cause this filing to be rejected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This form must be accompanied by appropriate fees.</I></FONT></TD>
    <TD STYLE="width: 56%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada Secretary of State Amend Designation - Before</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: right">Revised : 1-5-15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNANIMOUS WRITTEN CONSENT OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">The undersigned,
constituting all of the members of the Board of Directors (the &ldquo;Board&rdquo;) of Synthetic Biologics, Inc. (the &ldquo;Corporation&rdquo;)
and acting by written consent in lieu of a meeting in accordance with Section 78.315 of the Nevada Revised Statutes, hereby adopt
the following resolutions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt"><B>WHEREAS</B>,
the Board has previously approved the public offering of the securities of the Corporation in an amount up to $30,000,000 (the
 &ldquo;Offering&rdquo;) through the issuance of the following securities of the Corporation: (i) Class A Units, each unit comprised
of one share of common stock, par value $0.001 (the &ldquo;Common Stock&rdquo;), and one warrant to purchase one share of Common
Stock (a &ldquo;Warrant&rdquo; or the &ldquo;Warrants&rdquo;) and (ii) for any investor whose purchase of Class A Units would
otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99%
(or, at the election of the purchaser, 9.99%) of the Corporation&rsquo;s outstanding common stock immediately following the consummation
of the offering, Class B Units, each unit comprised of one share of Series B Convertible Preferred Stock and one Warrant (the
Class A Units and the securities included therein and the Class B Units and the securities included therein being referred to
as the &ldquo;<U>Securities</U>&rdquo;). in a <I>bona fide</I> public offering with A.G.P./Alliance Global Partners, as representative
of the underwriters (&ldquo;A.G.P.&rdquo;) on an underwritten firm commitment basis pursuant to the registration statement on
Form S-1, as amended (File No. 333-227400) filed with the U.S. Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) and which was declared effective by the
Commission on October 10, 2018; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt"><B>WHEREAS</B>,
the Corporation filed a Certificate of Designation with the Secretary of State of the State of Nevada on October 11, 2018 (the
 &ldquo;Certificate of Designation&rdquo;) designating 15,102 shares of its preferred stock as Series B Convertible Preferred Stock
and due to an administrative error on the part of A.G.P., the Corporation desires to correct this error and issue an additional
621 shares of preferred stock that are designated as Series B Convertible Preferred Stock, such that the total number of Series
B Convertible Preferred Stock that will be issued is 15,723 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt"><B>RESOLVED</B>,
that the appropriate officer of the Corporation (the &ldquo;<U>Authorized Officer</U>&rdquo;) be, and hereby is, authorized to
file with the Secretary of State of the State of Nevada an amendment to the Certificate of Designation for the Series B Convertible
Preferred Stock substantially in the form annexed hereto as <U>Exhibit A</U> to increase the number of shares of preferred stock
that are designated as Series B Convertible Preferred Stock to 15,723 Series B Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify; text-indent: 33pt">This consent is
being signed on October 11, 2018. This consent may be signed in counterparts, each of which shall be deemed an original and all
together shall constitute one and the same consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 201pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey J. Kraws</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey J. Kraws</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Scott L. Tarriff</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott L. Tarriff</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey Wolf</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Wolf</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>5
<FILENAME>tv504760_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>EXECUTION VERSION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Synthetic
Biologics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Corporate
Stock Transfer, Inc., as</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Warrant
Agent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Warrant
Agency Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Dated
as of October 15, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="background-color: white">WARRANT
AGENCY AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">WARRANT
AGENCY AGREEMENT, dated as of October 15, 2018 (&ldquo;Agreement&rdquo;), between Synthetic Biologics, Inc., a Nevada corporation
(the &ldquo;Company&rdquo;), and Corporate Stock Transfer, Inc., with offices located at 3200 Cherry Creek South Drive, Suite 430,
Denver, Colorado 80209 (the &ldquo;Warrant Agent&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">WITNESSETH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to a
registered offering by the Company of an aggregate of 2,520,000 Class A Units (each, a &ldquo;Class A Unit&rdquo; and collectively,
the &ldquo;Class A Units&rdquo;), each Class A Unit consisting of one share of the Company&rsquo;s common stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;), and a warrant to purchase one share of Common Stock (each, a &ldquo;Warrant&rdquo;
and collectively, the &ldquo;Warrants&rdquo;), and an aggregate of 15,723 Class B Units (each, a &ldquo;Class B Unit&rdquo; and
collectively, the &ldquo;Class B Units&rdquo;), each Class B Unit consisting of one share of Series B Convertible Preferred Stock,
par value $0.001 per share (the &ldquo;Preferred Stock&rdquo;), and a Warrant to purchase the number of shares as would have been
issued to such purchaser if they had purchased Class A Units based on the public offering price, pursuant to an effective registration
statement on Form S-1, as amended (File No. 333-227400) (the &ldquo;Registration Statement&rdquo;), the Company wishes to issue
the Warrants in book entry form entitling the respective holders of the Warrants (the &ldquo;Holders&rdquo;, which term shall include
a Holder&rsquo;s transferees, successors and assigns and &ldquo;Holder&rdquo; shall include, if the Warrants are held in &ldquo;street
name,&rdquo; a Participant (as defined below) or a designee appointed by such Participant) to purchase an aggregate of up to 18,620,998
shares of Common Stock (including Warrants potentially issued under the over-allotment option) upon the terms and subject to the
conditions hereinafter set forth (the &ldquo;Offering&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the shares of
Common Stock, Preferred Stock and Warrants to be issued in connection with the Offering shall be immediately separable and will
be issued separately, but will be purchased together in the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company wishes
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance,
registration, transfer, exchange, exercise and replacement of the Warrants and, in the Warrant Agent&rsquo;s capacity as the Company&rsquo;s
transfer agent, the delivery of the Warrant Shares (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 1.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Certain
Definitions. For purposes of this Agreement, the following terms have the meanings indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">&ldquo;Business
Day&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any
day on which the New York Stock Exchange is authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">&ldquo;Close
of Business&rdquo; on any given date means 5:00 p.m., New York City time, on such date; provided, however, that if such date is
not a Business Day it means 5:00 p.m., New York City time, on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">&ldquo;Person&rdquo;
means an individual, corporation, association, partnership, limited liability company, joint venture, trust, unincorporated organization,
government or political subdivision thereof or governmental agency or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">&ldquo;Warrant
Certificate&rdquo; means a certificate issued to a Holder, representing such number of Warrant Shares as is indicated therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">&ldquo;Warrant
Shares&rdquo; means the shares of Common Stock underlying the Warrants and issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All other capitalized terms
used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Appointment
of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the terms and
conditions hereof, and the Warrant Agent hereby accepts such appointment. The Company may from time to time appoint a Co-Warrant
Agent as it may, in its sole discretion, deem necessary or desirable. The Warrant Agent shall have no duty to supervise, and will
in no event be liable for the acts or omissions of, any co-Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Global
Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrants shall be issuable in book entry form (the &ldquo;Global Warrants&rdquo;). All of the Warrants shall initially be represented
by one or more Global Warrants deposited with the Warrant Agent and registered in the name of Cede &amp; Co., a nominee of The
Depository Trust Company (the &ldquo;Depositary&rdquo;), or as otherwise directed by the Depositary. Ownership of beneficial interests
in the Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the
Depositary or its nominee for each Global Warrant or (ii) institutions that have accounts with the Depositary (such institution,
with respect to a Warrant in its account, a &ldquo;Participant&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">If
the Depositary subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct
the Warrant Agent regarding other arrangements for book-entry settlement. In the event that the Warrants are not eligible for,
or it is no longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions
to the Depositary to deliver to the Warrant Agent for cancellation each Global Warrant, and the Company shall instruct the Warrant
Agent to deliver to each Holder a Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">A
Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate
Request Notice (as defined below). Upon written notice by a Holder to the Warrant Agent for the exchange of some or all of such
Holder&rsquo;s Global Warrants for a Warrant Certificate evidencing the same number of Warrants, which request shall be in the
form attached hereto as Annex A (a &ldquo;Warrant Certificate Request Notice&rdquo; and the date of delivery of such Warrant Certificate
Request Notice by the Holder, the &ldquo;Warrant Certificate Request Notice Date&rdquo; and the deemed surrender upon delivery
by the Holder of a number of Global Warrants for the same number of Warrants evidenced by a Warrant Certificate, a &ldquo;Warrant
Exchange&rdquo;), the Warrant Agent shall promptly effect the Warrant Exchange and shall promptly issue and deliver to the Holder
a Warrant Certificate for such number of Warrants in the name set forth in the Warrant Certificate Request Notice. Such Warrant
Certificate shall be dated the original issue date of the Warrants and shall be manually executed by an authorized signatory of
the Company. In connection with a Warrant Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the
Warrant Certificate to the Holder within three (3) Business Days of the Warrant Certificate Request Notice pursuant to the delivery
instructions in the Warrant Certificate Request Notice (&ldquo;Warrant Certificate Delivery Date&rdquo;). If the Company fails
for any reason to deliver to the Holder the Warrant Certificate subject to the Warrant Certificate Request Notice by the Warrant
Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares evidenced by such Warrant Certificate (based on the VWAP (as defined in the Warrant) of the Common Stock on the
Warrant Certificate Request Notice Date), $10 per Business Day (increasing to $20 per Business Day on the fifth Business Day after
such liquidated damages begin to accrue) for each Business Day after such Warrant Certificate Delivery Date until such Warrant
Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder rescinds such Warrant Exchange. The Company
covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed to be
the holder of the Warrant Certificate and, notwithstanding anything to the contrary set forth herein, the Warrant Certificate shall
be deemed for all purposes to contain all of the terms and conditions of the Warrants evidenced by such Warrant Certificate and
the terms of this Agreement, other than Section 3(c), which shall not apply to the Warrants evidenced by a Warrant Certificate.
In the event a beneficial owner requests a Warrant Exchange, upon issuance of the paper Warrant Certificate, the Company shall
act as warrant agent and the terms of the paper Warrant Certificate so issued shall exclusively govern in respect thereof. For
purposes of clarity, if there is a conflict between the express terms of this Agreement and any Warrant Certificate with respect
to the terms of the Warrants, the terms of such Warrant Certificate shall govern and control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Form
of Warrant. The Warrants, together with the form of election to purchase Common Stock (the &ldquo;Exercise Notice&rdquo;) and the
form of assignment to be printed on the reverse thereof, whether a Warrant Certificate or a Global Warrant, shall be substantially
in the form of Exhibit 1 hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Countersignature
and Registration. The Warrants shall be executed on behalf of the Company by its Chief Executive Officer or Chief Financial Officer,
either manually or by facsimile signature, and have affixed thereto the Company&rsquo;s seal or a facsimile thereof which shall
be attested by the Secretary or an Assistant Secretary of the Company, either manually or by facsimile signature. The Warrants
shall be countersigned by the Warrant Agent either manually or by facsimile signature and shall not be valid for any purpose unless
so countersigned. In case any officer of the Company who shall have signed a Warrant shall cease to be such officer of the Company
before countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant, nevertheless, may be countersigned
by the Warrant Agent, issued and delivered with the same force and effect as though the person who signed such Warrant had not
ceased to be such officer of the Company; and any Warrant may be signed on behalf of the Company by any person who, at the actual
date of the execution of such Warrant, shall be a proper officer of the Company to sign such Warrant, although at the date of the
execution of this Warrant Agreement any such person was not such an officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Warrant Agent will
keep or cause to be kept, at one of its offices, or at the office of one of its agents, books for registration and transfer of
the Warrant Certificates issued hereunder. Such books shall show the names and addresses of the respective Holders of the Warrant
Certificates, the number of warrants evidenced on the face of each of such Warrant Certificate and the date of each of such Warrant
Certificate. The Warrant Agent will create a special account for the issuance of Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Transfer,
Split Up, Combination and Exchange of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates. Subject
to the provisions of the Warrant and the last sentence of this first paragraph of Section 6 and subject to applicable law, rules
or regulations, or any &ldquo;stop transfer&rdquo; instructions the Company may give to the Warrant Agent, at any time after the
closing date of the Offering, and at or prior to the Close of Business on the Termination Date, any Warrant Certificate or Warrant
Certificates or Global Warrant or Global Warrants may be transferred, split up, combined or exchanged for another Warrant Certificate
or Warrant Certificates or Global Warrant or Global Warrants, entitling the Holder to purchase a like number of shares of Common
Stock as the Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants surrendered then entitled such Holder
to purchase. Any Holder desiring to transfer, split up, combine or exchange any Warrant Certificate or Global Warrant shall make
such request in writing delivered to the Warrant Agent, and shall surrender the Warrant Certificate or Warrant Certificates to
be transferred, split up, combined or exchanged at the principal office of the Warrant Agent, provided that no such surrender is
applicable to the Holder of a Global Warrant. Any requested transfer of Warrants, whether a Global Warrant or a Warrant Certificate,
shall be accompanied by reasonable evidence of authority of the party making such request that may be required by the Warrant Agent.
Thereupon the Warrant Agent shall, subject to the last sentence of this first paragraph of Section 6, countersign and deliver to
the Person entitled thereto any Warrant Certificate or Global Warrant, as the case may be, as so requested. The Company may require
payment from the Holder of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any
transfer, split up, combination or exchange of Warrants. The Company shall compensate the Warrant Agent per the fee schedule mutually
agreed upon by the parties hereto and provided separately on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon receipt by the Warrant
Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence
shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and,
in case of loss, theft or destruction, of indemnity in customary form and amount, and satisfaction of any other reasonable requirements
established by Section 8-405 of the Uniform Commercial Code as in effect in the State of Nevada, and reimbursement to the Company
and the Warrant Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of
the Warrant Certificate if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Warrant
Agent for delivery to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Exercise
of Warrants; Exercise Price; Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrants shall be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be exercisable and shall terminate
and become void, and all rights thereunder and under this Agreement shall cease, at or prior to the Close of Business on the Termination
Date. Subject to the foregoing and to Section 7(b) below, the Holder of a Warrant may exercise the Warrant in whole or in part
upon providing the items required by Section 7(c) below to the Warrant Agent at the principal office of the Warrant Agent or to
the office of one of its agents as may be designated by the Warrant Agent from time to time. In the case of the Holder of a Global
Warrant, the Holder shall deliver the executed Exercise Notice and payment of the Exercise Price pursuant to Section 2(a) of the
Warrant. Notwithstanding any other provision in this Agreement, a holder whose interest in a Global Warrant is a beneficial interest
in a Global Warrant held in book-entry form through the Depositary (or another established clearing corporation performing similar
functions), shall effect exercises by delivering to the Depositary (or such other clearing corporation, as applicable) the appropriate
instruction form for exercise, complying with the procedures to effect exercise that are required by the Depositary (or such other
clearing corporation, as applicable). The Company acknowledges that the bank accounts maintained by the Warrant Agent in connection
with the services provided under this Agreement will be in its name and that the Warrant Agent may receive investment earnings
in connection with the investment at Warrant Agent risk and for its benefit of funds held in those accounts from time to time.
Neither the Company nor the Holders will receive interest on any deposits or Exercise Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Upon
receipt of an Exercise Notice for a cashless exercise pursuant to Section 2(c) of the Warrant (each, a &ldquo;Cashless Exercise&rdquo;),
the Company will promptly calculate and transmit to the Warrant Agent the number of Warrant Shares issuable in connection with
such Cashless Exercise and deliver a copy of the Exercise Notice to the Warrant Agent, which shall issue such number of Warrant
Shares in connection with such Cashless Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Upon
the Warrant Agent&rsquo;s receipt, at or prior to the Close of Business on the Termination Date set forth in a Warrant, of the
executed Exercise Notice, accompanied by payment of the Exercise Price pursuant to Section 2(a) of the Warrant, the shares to be
purchased (other than in the case of a Cashless Exercise), an amount equal to any applicable tax, governmental charge or expense
reimbursement referred to in Section 6 in cash, or by certified check or bank draft payable to the order of the Company and, in
the case of an exercise of a Warrant in the form of a Warrant Certificate for all of the Warrant Shares represented thereby, the
Warrant Certificate, the Warrant Agent shall cause the Warrant Shares underlying such Warrant to be delivered to or upon the order
of the Holder of such Warrant, registered in such name or names as may be designated by such Holder, no later than the Warrant
Share Delivery Date. If the Company is then a participant in the DWAC system of the Depositary and either (A) there is an effective
registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant
is being exercised via Cashless Exercise, then the certificates for Warrant Shares shall be transmitted by the Warrant Agent to
the Holder by crediting the account of the Holder&rsquo;s broker with the Depositary through its DWAC system. For the avoidance
of doubt, if the Company becomes obligated to pay any amounts to any Holders pursuant to Section 2(d)(i) or 2(d)(iv) of the Warrant,
such obligation shall be solely that of the Company and not that of the Warrant Agent. Notwithstanding anything else to the contrary
in this Agreement, except in the case of a Cashless Exercise, if any Holder fails to duly deliver payment to the Warrant Agent
of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of such Holder&rsquo;s Warrant
as set forth in Section 7(a) hereof, the Warrant Agent will not obligated to deliver certificates representing any such Warrant
Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Warrant Share Delivery Date shall be
deemed extended by one day for each day (or part thereof) until such payment is delivered to the Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company
maintained with the Warrant Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise
the Company via telephone at the end of each day on which funds for the exercise of any Warrant are received of the amount so deposited
to its account. The Warrant Agent shall promptly confirm such telephonic advice to the Company in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">In
case the Holder of any Warrant Certificate exercises fewer than all Warrants evidenced thereby and surrenders such Warrant Certificate
in connection with such partial exercise, a new Warrant Certificate evidencing the number of Warrant Shares equivalent to the number
of Warrant Shares remaining unexercised may be issued by the Warrant Agent to the Holder of such Warrant Certificate or to his
duly authorized assigns in accordance with Section 2(d)(ii) of the Warrant, subject to the provisions of Section 6 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Cancellation
and Destruction of Warrant Certificates. All Warrant Certificates surrendered for the purpose of exercise, transfer, split up,
combination or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation
or in canceled form, or, if surrendered to the Warrant Agent, shall be canceled by it, and no Warrant Certificates shall be issued
in lieu thereof except as expressly permitted by any of the provisions of this Agreement. The Company shall deliver to the Warrant
Agent for cancellation and retirement, and the Warrant Agent shall so cancel and retire, any other Warrant Certificate purchased
or acquired by the Company otherwise than upon the exercise thereof. The Warrant Agent shall deliver all canceled Warrant Certificates
to the Company, or shall, at the written request of the Company, destroy such canceled Warrant Certificates, and in such case shall
deliver a certificate of destruction thereof to the Company, subject to any applicable law, rule or regulation requiring the Warrant
Agent to retain such canceled certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;<FONT STYLE="background-color: white">Certain
Representations; Reservation and Availability of Shares of Common Stock or Cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">This
Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery
hereof by the Warrant Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company
in accordance with its terms, and the Warrants have been duly authorized, executed and issued by the Company and, assuming due
authentication thereof by the Warrant Agent pursuant hereto and payment therefor by the Holders as provided in the Registration
Statement, constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their
terms and entitled to the benefits thereof; in each case except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium and other similar laws relating to or affecting creditors&rsquo; rights generally or by general equitable principles
(regardless of whether such enforceability is considered in a proceeding in equity or at law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">As
of the date hereof and prior to the Offering, the authorized capital stock of the Company consists of (i) 200,000,000 shares of
authorized Common Stock, of which 7,208,320 shares of Common Stock are issued and outstanding, and (ii) 10,000,000 shares of authorized
preferred stock of which 120,000 are issued and outstanding. As of the date hereof there are 18,620,998 shares of Common Stock
reserved for issuance upon exercise of the Warrants inclusive of any Warrants the Underwriter may acquire upon exercise of its
over-allotment option described in the Registration Statement. Except as disclosed in the Registration Statement, there are no
other outstanding obligations, warrants, options or other rights to subscribe for or purchase from the Company any class of capital
stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of
Common Stock or its authorized and issued shares of Common Stock held in its treasury, free from preemptive rights, the number
of shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent will create a special account for the issuance of Common Stock upon the exercise of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges
which may be payable in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common
Stock upon exercise of the Warrants. The Company shall not, however, be required to pay any tax or governmental charge which may
be payable in respect of any transfer involved in the transfer or delivery of Warrant Certificates or the issuance or delivery
of certificates for Common Stock in a name other than that of the Holder of the Warrant Certificate evidencing Warrants surrendered
for exercise or to issue or deliver any certificate for shares of Common Stock upon the exercise of any Warrants until any such
tax or governmental charge shall have been paid (any such tax or governmental charge being payable by the Holder of such Warrant
Certificate at the time of surrender) or until it has been established to the Company&rsquo;s reasonable satisfaction that no such
tax or governmental charge is due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Common
Stock Record Date. Each Holder shall be deemed to have become the holder of record for the Warrant Shares pursuant to Section 2(d)(i)
of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Adjustment
of Exercise Price, Number of Shares of Common Stock or Number of the Company Warrants. The Exercise Price, the number of shares
covered by each Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided in Section
3 of the Warrant. In the event that at any time, as a result of an adjustment made pursuant to Section 3 of the Warrant, the Holder
of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than shares
of Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment
from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares contained
in Section 3 of the Warrant, and the provisions of Sections 7, 9 and 13 of this Agreement with respect to the shares of Common
Stock shall apply on like terms to any such other shares. All Warrants originally issued by the Company subsequent to any adjustment
made to the Exercise Price pursuant to the Warrant shall evidence the right to purchase, at the adjusted Exercise Price, the number
of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment
as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Certification
of Adjusted Exercise Price or Number of Shares of Common Stock. Whenever the Exercise Price or the number of shares of Common Stock
issuable upon the exercise of each Warrant is adjusted as provided in Section 11 or 13, the Company shall (a) promptly prepare
a certificate setting forth the Exercise Price of each Warrant as so adjusted, and a brief statement of the facts accounting for
such adjustment, (b) promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate
and (c) instruct the Warrant Agent to send a brief summary thereof to each Holder of a Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Fractional
Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Company shall not issue fractions of Warrants or distribute a Global Warrant or Warrant Certificates that evidence fractional Warrants.
Whenever any fractional Warrant would otherwise be required to be issued or distributed, the actual issuance or distribution shall
reflect a rounding of such fraction either up or down to the nearest whole Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates that evidence
fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or
distributed, the actual issuance or distribution in respect thereof shall be made in accordance with Section 2(d)(v) of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Conditions
of the Warrant Agent&rsquo;s Obligations. The Warrant Agent accepts its obligations herein set forth upon the terms and conditions
hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the Holders from
time to time of the Warrant shall be subject:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Compensation
and Indemnification. The Company agrees promptly to pay the Warrant Agent the compensation detailed on Exhibit 2 hereto for all
services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable out-of-pocket expenses (including reasonable
counsel fees) incurred without gross negligence, bad faith or willful misconduct by the Warrant Agent in connection with the services
rendered hereunder by the Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it harmless against,
any loss, liability or expense incurred without gross negligence, bad faith or willful misconduct on the part of the Warrant Agent,
arising out of or in connection with its acting as Warrant Agent hereunder, including the reasonable costs and expenses of defending
against any claim of such liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Agent
for the Company. In acting under this Warrant Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting
solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the Holders
of Warrant Certificates or beneficial owners of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Counsel.
The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the Company, and the written advice
of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by
it hereunder in good faith and in accordance with the advice of such counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Documents.
The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or omitted by it in reliance
upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably
believed by it to be genuine and to have been presented or signed by the proper parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Certain
Transactions. The Warrant Agent, and its officers, directors and employees, may become the owner of, or acquire any interest in,
Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted
by applicable law, it or they may engage or be interested in any financial or other transaction with the Company and may act on,
or as depositary, trustee or agent for, any committee or body of Holders of Warrant Securities or other obligations of the Company
as freely as if it were not the Warrant Agent hereunder. Nothing in this Warrant Agreement shall be deemed to prevent the Warrant
Agent from acting as trustee under any indenture to which the Company is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">No
Liability for Interest. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any
monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">No
Liability for Invalidity. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or any of
the Warrant Certificates (except as to the Warrant Agent&rsquo;s countersignature thereon).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">No
Responsibility for Representations. The Warrant Agent shall not be responsible for any of the recitals or representations herein
or in the Warrant Certificates (except as to the Warrant Agent&rsquo;s countersignature thereon), all of which are made solely
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">No
Implied Obligations. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrants specifically
set forth and no implied duties or obligations shall be read into this Agreement or the Warrants against the Warrant Agent. The
Warrant Agent shall not be under any obligation to take any action hereunder which may tend to involve it in any expense or liability,
the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be
accountable or under any duty or responsibility for the use by the Company of any of the Warrants authenticated by the Warrant
Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the
Warrants. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance of its
covenants or agreements contained herein or in the Warrants or in the case of the receipt of any written demand from a Holder of
a Warrant Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility
to initiate or attempt to initiate any proceedings at law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Purchase
or Consolidation or Change of Name of Warrant Agent. Any corporation into which the Warrant Agent or any successor Warrant Agent
may be merged or with which it may be consolidated, or any corporation resulting from any merger or consolidation to which the
Warrant Agent or any successor Warrant Agent shall be party, or any corporation succeeding to the corporate trust business of the
Warrant Agent or any successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution
or filing of any paper or any further act on the part of any of the parties hereto, provided that such corporation would be eligible
for appointment as a successor Warrant Agent under the provisions of Section 17. In case at the time such successor Warrant Agent
shall succeed to the agency created by this Agreement any of the Warrants shall have been countersigned but not delivered, any
such successor Warrant Agent may adopt the countersignature of the predecessor Warrant Agent and deliver such Warrants so countersigned;
and in case at that time any of the Warrants shall not have been countersigned, any successor Warrant Agent may countersign such
Warrants either in the name of the predecessor Warrant Agent or in the name of the successor Warrant Agent; and in all such cases
such Warrants shall have the full force provided in the Warrants and in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In case at any time the
name of the Warrant Agent shall be changed and at such time any of the Warrants shall have been countersigned but not delivered,
the Warrant Agent may adopt the countersignature under its prior name and deliver Warrants so countersigned; and in case at that
time any of the Warrants shall not have been countersigned, the Warrant Agent may countersign such Warrants either in its prior
name or in its changed name; and in all such cases such Warrants shall have the full force provided in the Warrants and in this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Duties
of Warrant Agent. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and
conditions, all of which the Company, by its acceptance hereof, shall be bound:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent may consult with legal counsel reasonably acceptable to the Company (who may be legal counsel for the Company), and
the opinion of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken
or omitted by it in good faith and in accordance with such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Whenever
in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter
be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence
in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate
signed by the Chief Executive Officer or Chief Financial Officer of the Company; and such certificate shall be full authentication
to the Warrant Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon
such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Subject
to the limitation set forth in Section 14, the Warrant Agent shall be liable hereunder only for its own gross negligence, bad faith
or willful misconduct, or for a breach by it of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or
in the Warrants (except its countersignature thereof) by the Company or be required to verify the same, but all such statements
and recitals are and shall be deemed to have been made by the Company only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery
hereof (except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant (except
its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained
in this Agreement or in any Warrant; nor shall it be responsible for the adjustment of the Exercise Price or the making of any
change in the number of shares of Common Stock required under the provisions of Section 11 or 13 or responsible for the manner,
method or amount of any such change or the ascertaining of the existence of facts that would require any such adjustment or change
(except with respect to the exercise of Warrants evidenced by Warrant Certificates after actual notice of any adjustment of the
Exercise Price); nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or
reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of
Common Stock will, when issued, be duly authorized, validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Each
party hereto agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and
delivered all such further and other acts, instruments and assurances as may reasonably be required by the other party hereto for
the carrying out or performing by any party of the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief
Executive Officer or Chief Financial Officer of the Company, and to apply to such officers for advice or instructions in connection
with its duties, and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken
by it in good faith in accordance with instructions of any such officer, provided Warrant Agent carries out such instructions without
gross negligence, bad faith or willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants
or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested,
or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this
Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal
entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself
or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect
or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct,
provided reasonable care was exercised in the selection and continued employment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Change
of Warrant Agent. The Warrant Agent may resign and be discharged from its duties under this Agreement upon 30 days&rsquo; notice
in writing sent to the Company and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates.
The Company may remove the Warrant Agent or any successor Warrant Agent upon 30 days&rsquo; notice in writing, sent to the Warrant
Agent or successor Warrant Agent, as the case may be, and to each transfer agent of the Common Stock, and to the Holders of the
Warrant Certificates. If the Warrant Agent shall resign or be removed or shall otherwise become incapable of acting, the Company
shall appoint a successor to the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after
such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Warrant
Agent or by the Holder of a Warrant Certificate (who shall, with such notice, submit his Warrant Certificate for inspection by
the Company), then the Holder of any Warrant Certificate may apply to any court of competent jurisdiction for the appointment of
a new Warrant Agent. Any successor Warrant Agent, whether appointed by the Company or by such a court, shall be a corporation organized
and doing business under the laws of the United States or of a state thereof, in good standing, which is authorized under such
laws to exercise corporate trust powers and is subject to supervision or examination by federal or state authority and which has
at the time of its appointment as Warrant Agent a combined capital and surplus of at least $50,000,000. After appointment, the
successor Warrant Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally
named as Warrant Agent without further act or deed; but the predecessor Warrant Agent shall deliver and transfer to the successor
Warrant Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or
deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof
in writing with the predecessor Warrant Agent and each transfer agent of the Common Stock, and mail a notice thereof in writing
to the Holders of the Warrant Certificates. However, failure to give any notice provided for in this Section 17, or any defect
therein, shall not affect the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the
successor Warrant Agent, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Issuance
of New Warrants. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company may, at
its option, issue a new Global Warrant or Warrant Certificates, if any, evidencing Warrants in such form as may be approved by
its Board of Directors to reflect any adjustment or change in the Exercise Price per share and the number or kind or class of shares
of stock or other securities or property purchasable under the Global Warrant or Warrant Certificates, if any, made in accordance
with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Notices.
Notices or demands authorized by this Agreement to be given or made (i) by the Warrant Agent or by the Holder of any Warrant Certificate
to or on the Company, (ii) subject to the provisions of Section 17, by the Company or by the Holder of any Warrant Certificate
to or on the Warrant Agent or (iii) by the Company or the Warrant Agent to the Holder of any Warrant Certificate, shall be deemed
given (a) on the date delivered, if delivered personally, (b) on the first Business Day following the deposit thereof with Federal
Express or another recognized overnight courier, if sent by Federal Express or another recognized overnight courier, (c) on the
fourth Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt
requested), and (d) the time of transmission, if such notice or communication is delivered via facsimile or email attachment at
or prior to 5:30 p.m. (New York City time) on a Business Day and (e) the next Business Day after the date of transmission, if such
notice or communication is delivered via facsimile or email attachment on a day that is not a Business Day or later than 5:30 p.m.
(New York City time) on any Business Day, in each case to the parties at the following addresses (or at such other address for
a party as shall be specified by like notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="background-color: white">Synthetic Biologics,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="background-color: white">9605 Medical Center
Drive, Suite 270</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="background-color: white">Rockville, Maryland
20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="background-color: white">Attention: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
to the Warrant Agent, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="background-color: white">Corporate Stock
Transfer, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="background-color: white">3200 Cherry Creek
South Drive, Suite 430</FONT><BR>
<FONT STYLE="background-color: white">Denver, Colorado 80209</FONT><BR>
<FONT STYLE="background-color: white">Attention: Carylyn Bell</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For any notice delivered
by email to be deemed given or made, such notice must be followed by notice sent by overnight courier service to be delivered on
the next business day following such email, unless the recipient of such email has acknowledged via return email receipt of such
email.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">If
to the Holder of any Warrant Certificate, to the address of such Holder as shown on the registry books of the Company. Any notice
required to be delivered by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company.
Notwithstanding any other provision of this Agreement, where this Agreement provides for notice of any event to a Holder of any
Warrant Certificate, for a Global Warrant, such notice shall be sufficiently given if given to the Depositary (or its designee)
pursuant to the procedures of the Depositary or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Supplements
and Amendments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">The
Company and the Warrant Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Warrant
Certificates in order to cure any ambiguity, to correct or supplement any provision contained herein which may be defective or
inconsistent with any other provisions herein, or to make any other provisions with regard to matters or questions arising hereunder
which the Company and the Warrant Agent may deem necessary or desirable and which shall not adversely affect the interests of the
Holders of the Warrants Certificates in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">In
addition to the foregoing, with the consent of Holders of Warrants, the Company and the Warrant Agent may modify this Agreement
for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Warrant Agreement
or modifying in any manner the rights of the Holders of the Warrant Certificates; provided, however, that no modification of the
terms (including but not limited to the adjustments described in Section 11) upon which the Warrants are exercisable or reducing
the percentage required for consent to modification of this Agreement may be made without the consent of the Holder of each outstanding
warrant certificate affected thereby. As a condition precedent to the Warrant Agent&rsquo;s execution of any amendment, the Company
shall deliver to the Warrant Agent a certificate from a duly authorized officer of the Company that states that the proposed amendment
complies with the terms of this Section 20.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Successors.
All covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to
the benefit of their respective successors and assigns hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Benefits
of this Agreement. Nothing in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrant
Certificates and the Warrant Agent any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall
be for the sole and exclusive benefit of the Company, the Warrant Agent and the Holders of the Warrant Certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Governing
Law. This Agreement and each Warrant issued hereunder shall be governed by, and construed in accordance with, the laws of the State
of New York without giving effect to the conflicts of law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Counterparts.
This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to
be an original, and all such counterparts shall together constitute but one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Captions.
The captions of the sections of this Agreement have been inserted for convenience only and shall not control or affect the meaning
or construction of any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Information.
The Company agrees to promptly provide to the Holders of the Warrants any information it provides to all holders of the Common
Stock, except to the extent any such information is publicly available on the EDGAR system (or any successor thereof) of the Securities
and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section 27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<FONT STYLE="background-color: white">Force
Majeure. Notwithstanding anything to the contrary contained herein, Warrant Agent shall not be liable for any delays or failures
in performance resulting from acts beyond its reasonable control including, without limitation, acts of God, terrorist acts, shortage
of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures
or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil unrest, it being understood
that the Warrant Agent shall use reasonable best efforts which are consistent with accepted practices in the banking industry to
resume performance as soon as practicable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">(Signature
Page Follows)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="background-color: white">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Steven A. Shallcross</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Name:</FONT></TD>
    <TD>Steven A. Shallcross</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Title:</FONT></TD>
    <TD>Interim Chief Executive Officer and Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="background-color: white">CORPORATE STOCK TRANSFER, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Carylyn Bell</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Name:</FONT></TD>
    <TD>Carylyn Bell</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Title:</FONT></TD>
    <TD>President</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Annex
A: Form of Warrant Certificate Request Notice</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">WARRANT
CERTIFICATE REQUEST NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">To: Corporate
Stock Transfer, Inc. as Warrant Agent for Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The undersigned
Holder of Common Stock Purchase Warrants (&ldquo;Warrants&rdquo;) in the form of Global Warrants issued by the Company hereby elects
to receive a Warrant Certificate evidencing the Warrants held by the Holder as specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD><FONT STYLE="background-color: white">Name of Holder of Warrants in form of Global Warrants: _____________________________</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD><FONT STYLE="background-color: white">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in
form of Global Warrants): ________________________________</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD><FONT STYLE="background-color: white">Number of Warrants in name of Holder in form of Global Warrants: ___________________</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD><FONT STYLE="background-color: white">Number of Warrants for which Warrant Certificate shall be issued: __________________</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD><FONT STYLE="background-color: white">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant
Certificate, if any: ___________</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD><FONT STYLE="background-color: white">Warrant Certificate shall be delivered to the following address:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">__________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">__________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">__________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">__________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The undersigned
hereby acknowledges and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the
Holder is deemed to have surrendered the number of Warrants in form of Global Warrants in the name of the Holder equal to the number
of Warrants evidenced by the Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">[SIGNATURE OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Name of Investing Entity:
___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Signature of Authorized Signatory
of Investing Entity: _____________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Name of Authorized Signatory:
_______________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Title of Authorized Signatory:
________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Date: ______________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">Exhibit
1: Form of Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">COMMON
STOCK PURCHASE WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">SYNTHETIC
BIOLOGICS, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Warrant
Shares: _______ Initial Exercise Date: October 15, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;Warrant&rdquo;) certifies that, for value received, _____________ or its assigns (the
 &ldquo;Holder&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after October 15, 2018 (the &ldquo;Initial Exercise Date&rdquo;) and on or prior to 5:00 p.m. (New York
City time) on October 15, 2023 (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from Synthetic
Biologics, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), up to ______ shares (as subject to adjustment hereunder, the
 &ldquo;Warrant Shares&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal
to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security
held in book-entry form and the Depository Trust Company or its nominee (&ldquo;DTC&rdquo;) shall initially be the sole registered
holder of this Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms
of the Warrant Agency Agreement, in which case this sentence shall not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Section 1. <FONT STYLE="background-color: white">Definitions.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Affiliate&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Bid
Price&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Board
of Directors&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Business
Day&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Commission&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Common
Stock&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Common
Stock Equivalents&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Exchange
Act&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Exempt
Issuance&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the
Company, (b) securities upon the exercise or exchange of or conversion of any securities issued under the Registration Statement
and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the
date of this Warrant, provided that such securities have not been amended since the date of this Warrant to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are
issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit
the filing of any registration statement in connection therewith, and provided that any such issuance shall only be to a Person
(or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset
in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to
the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities; it being agreed and understood that issuances
pursuant the Company&rsquo;s agreement with Cedars-Sinai Medical Center are Exempt Issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Person&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Registration
Statement&rdquo; means the Company&rsquo;s registration statement on Form S-1, as amended (File No. 333-227400).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Securities
Act&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Trading
Day&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Trading
Market&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Transfer
Agent&rdquo; means Corporate Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 3200 Cherry
Creek South Drive, Suite 430, Denver, Colorado 80209 and a facsimile number of 303-282-5800, and any successor transfer agent of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;VWAP&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Warrant
Agency Agreement&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Warrant
Agent&rdquo; means the Transfer Agent and any successor warrant agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Warrants&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Section 2. <FONT STYLE="background-color: white">Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;Notice
of Exercise&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to
the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)
Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Notwithstanding
the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing
this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall
effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the
appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other
clearing corporation, as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant
to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply, provided, however, a beneficial holder
shall have all of the rights and remedies of a &ldquo;Holder&rdquo; hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $1.38, subject to adjustment hereunder (the
 &ldquo;Exercise Price&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Cashless
Exercise. If at any time after the date hereof, there is no effective registration statement registering, or no current prospectus
available for, the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part,
at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">(A) <FONT STYLE="background-color: white">=
as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as
defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option
of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)
the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of
Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">(B) <FONT STYLE="background-color: white">=
the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="background-color: white">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">If Warrant
Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees
not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">d)</TD><TD STYLE="text-align: justify">Mechanics of Exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Delivery of Warrant Shares Upon Exercise. The Company shall
cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of
the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an effective
registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant
is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant
to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2)
Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate
Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;Warrant Share Delivery Date&rdquo;), all subject to receipt of
any cash payments required by the Holder. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of
a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to
the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the
Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;Standard
Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Delivery of New Warrants Upon Exercise. If this Warrant shall
have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the
time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Rescission Rights. If the Company fails to cause the Transfer
Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder
will have the right to rescind such exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">iv.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Compensation for Buy-In on Failure to Timely Deliver Warrant
Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent
to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;Buy-In&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely
deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">v.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">No Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder
would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in
respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole
share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">vi.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Charges, Taxes and Expenses. Issuance of Warrant Shares shall
be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such
Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name
of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares
are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by
the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment
of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required
for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">vii.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Closing of Books. The Company will not close its stockholder
books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder&rsquo;s
<FONT STYLE="background-color: white">Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder
shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after
giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the
Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
(such Persons, &ldquo;Attribution Parties&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and
its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as
set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and
the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to
any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common
Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or
(C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial
Ownership Limitation&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of and Warrants, 9.99%) of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Section 3. <FONT STYLE="background-color: white">Certain
Adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Adjustment
Upon Issuance of Shares of Common Stock. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant
is outstanding, shall sell or grant any option to purchase, or otherwise dispose of or issue (or announce any offer, sale, grant
or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less
than the Exercise Price then in effect (such lower price, the &ldquo;Base Share Price&rdquo; and such issuances collectively, a
 &ldquo;Dilutive Issuance&rdquo;) (it being understood and agreed that if the Company sells securities as a unit, any warrant included
in the unit shall be deemed to have an effective price equal to its exercise price and any common stock include in the unit shall
be deemed to have an effective price equal to the unit price and if the holder of the Common Stock or Common Stock Equivalents
so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise
or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance,
be entitled to receive shares of Common Stock at an effective price per share that is less than the Exercise Price, such issuance
shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price),
then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance (i) (excluding securities
issued pursuant to any at-the-market or similar agreement, including but not limited to, the agreement the Company entered into
on August 5, 2016 (as such agreement may be amended or replaced) with FBR Capital Markets &amp; Co. now known as B. Riley FBR,
Inc. (each such issuance, an &ldquo;ATM Issuance&rdquo;)), the Exercise Price shall be reduced and only reduced to equal the Base
Share Price; (ii) involving securities issued pursuant to an ATM Issuance, the Exercise Price shall be reduced and only reduced
to the greater of the Base Share Price or fifty percent (50%) of the Exercise Price; provided, however that during the two year
period after issuance of this Warrant, the Company shall not issue any securities pursuant to an ATM Issuance at a price below
fifty percent (50%) of the Exercise Price. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this
Section 3(a) in respect of an Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day following
the issuance or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 3(a), indicating therein
the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice,
the &ldquo;Dilutive Issuance Notice&rdquo;). For purposes of clarification, whether or not the Company provides a Dilutive Issuance
Notice pursuant to this Section 3(a), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number
of Warrant Shares based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in
the Notice of Exercise. The Company shall have no right to voluntarily lower the exercise or conversion price of any security outstanding
on the date of issuance of the Warrant below the Exercise Price other than in accordance with the terms of such security without
the approval of holders of a majority of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(b) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Subsequent
Rights Offerings. In addition to any adjustments pursuant to Sections 3(a) and 3(b) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right
to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, that, to the extent that the Holder's right to participate in any such Distribution would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such
extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant
has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held
in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;Fundamental Transaction&rdquo;), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">g)</TD><TD STYLE="text-align: justify">Notice to Holder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Adjustment to Exercise Price. Whenever the Exercise Price
is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email
a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and
setting forth a brief statement of the facts requiring such adjustment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Notice to Allow Exercise by Holder. If (A) the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring
cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval
of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall
authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case,
the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it
shall appear upon the Warrant Register of the Company, at least 5 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record
to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice; provided further that no notice shall be required if
the information is disseminated in a press release or document filed with the SEC. To the extent that any notice provided in this
Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Section 4. <FONT STYLE="background-color: white">Transfer
of Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Transferability.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this
Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder
or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or
combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original issuance
date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Warrant
Register. The Warrant Agent (or, in the event a Holder elects to receive a Warrant in certificated form, the Company) shall register
this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant Register&rdquo;), in the name of
the record Holder hereof from time to time. The Warrant Agent and the Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Section 5. <FONT STYLE="background-color: white">Miscellaneous.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and
in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of
such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">d)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Authorized Shares.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The Company
covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New
York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be
reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">Notices.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized
overnight courier service, addressed to the Company, at Synthetic Biologics, Inc., 9605 Medical Center Drive, Suite 270, Rockville,
Maryland 20850 Attention: Chief Executive Officer, email address: sshallcross@syntheticbiologics.com, or such other facsimile number,
email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, e-mail address or address
of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on
any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by
U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to
the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">Warrant
Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject
to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant
Agency Agreement, the provisions of this Warrant shall govern and be controlling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">(Signature
Page Follows)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">IN WITNESS
WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="background-color: white">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">Title:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">NOTICE
OF EXERCISE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">TO: [
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt; background-color: white">&uml;</FONT>
<FONT STYLE="background-color: white">in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt; background-color: white">&uml;</FONT>
<FONT STYLE="background-color: white">if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable
pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The Warrant
Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">[SIGNATURE OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Name of Investing Entity:
_______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Signature of Authorized Signatory
of Investing Entity: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Name of Authorized Signatory:
___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Title of Authorized Signatory:
____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Date: _______________________________________________________________________________________</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="background-color: white">EXHIBIT
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">(To assign
the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">FOR VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%"><FONT STYLE="background-color: white">Name:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="background-color: white">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: white">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="background-color: white">Phone Number:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="background-color: white">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Dated: _______________ __,
______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Holder&rsquo;s Signature:______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Holder&rsquo;s Address:_______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>tv504760_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="tv504760_ex99-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Synthetic Biologics Prices $18,000,000 Public
Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rockville,
MD, October 11, 2018 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> (NYSE American: SYN) (&ldquo;Synthetic Biologics&rdquo;
or the &ldquo;Company&rdquo;), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome
to protect and restore the health of patients, announced today the pricing of an underwritten public offering with expected total
gross proceeds of $18,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
The Company expects to use the net proceeds from this offering to fund its and its subsidiaries&rsquo; preclinical and clinical
programs and for working capital and general corporate purposes, including to acquire, license or invest in complementary businesses,
technologies, product candidates or other intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities offered by the Company consist
of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at
a combined price of $1.15, and (ii) Class B Units consisting of 15,102 shares of Series B Convertible Preferred Stock, with a stated
value of $1,000 per share, and convertible into an aggregate of 13,132,173 shares of Common Stock, and Warrants to purchase 13,132,173
shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance and will expire five
years from the date of issuance. The Company has granted the underwriters a 45-day option to purchase additional shares of Common
Stock and/or additional Warrants to purchase shares of Common Stock, in amounts up to 15% of the Common Stock, Warrants and/or
Common Stock issuable upon conversion of the Series B Convertible Preferred Stock included in the Class B Units sold in the offering.
The shares of Common Stock and the accompanying Warrants included in the Class A Units and Class B Units can only be purchased
together in this offering but will be issued separately and will be immediately separable upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offering is expected to close on October
15, 2018, subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A.G.P./Alliance Global Partners is acting as
the sole book-running manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A registration statement relating to these
securities has been filed with the Securities and Exchange Commission (the &quot;SEC&quot;) and was declared effective on October
10, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offering is being made only by means of
a prospectus forming part of the effective registration statement. A copy of the prospectus relating to the offering may be obtained,
when available, by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone
at 212-624-2006 or email: <U>prospectus@allianceg.com</U>. Investors may also obtain these documents at no cost by visiting the
SEC's website at <U>http://www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release shall not constitute an
offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Synthetic Biologics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore
the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed
to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention
of <I>C. difficile</I> infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR),
and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying
cause of irritable bowel syndrome with constipation (IBS-C). The Company&rsquo;s preclinical pursuits include an oral formulation
of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody
therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria
(PKU). For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements
can be identified by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements with respect to this offering and the
successful execution of the Company's business strategy, including its intended use of proceeds from this offering. These forward-looking
statements are based upon management&rsquo;s beliefs, expectations and assumptions as of the date of this press release and are
subject to a number of substantial risks and uncertainties, many of which are difficult to predict and could cause actual results
to differ materially and adversely from current beliefs, expectations and assumptions from those set forth, projected or implied
by any such forward-looking statements. Important factors that could cause actual results to differ materially from those reflected
in Synthetic Biologics&rsquo; forward-looking statements include, among others, market conditions and the satisfaction of customary
closing conditions related to the proposed public offering, including the underwriter&rsquo;s exercise of their option to purchase
additional securities, as well as risks and uncertainties associated with the Company&rsquo;s business and finances in general,
including Synthetic Biologics' ability to regain compliance with the continued listing standards of the NYSE American by September
2, 2019, Synthetic Biologics' ability to comply with other continued listing requirements of the NYSE American, the ability of
its product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic
Biologics' clinical trials enrolling as expected, a failure to receive the necessary regulatory approvals for commercialization
of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a failure of Synthetic Biologics' clinical
trials, and those conducted by investigators, for its product candidates to be commenced or completed on time or to achieve desired
results and benefits, a failure of Synthetic Biologics' clinical trials to enroll patients as expected or receive anticipated funding,
a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics' inability to maintain
its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize
products, Synthetic Biologics' ability to achieve acceptance of its product candidates in the marketplace and the successful development,
marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete or non-competitive,
the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and remaining profitable,
Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and development activities,
a loss of any of Synthetic Biologics' key scientists or management personnel and the other risk factors described in the preliminary
prospectus relating to this offering and the risk factors incorporated by reference therein from Synthetic Biologics&rsquo; most
recent annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission (SEC) on February 22, 2018, and
its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is
provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Vincent I. Perrone, Director, Corporate Communication,
(240) 660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>tv504760_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv504760_ex99-2img2.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>Synthetic Biologics Announces Closing of $18,639,000 Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rockville,
MD, October 15, 2018 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> (NYSE American: SYN) (&ldquo;Synthetic Biologics&rdquo;
or the &ldquo;Company&rdquo;), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome
to protect and restore the health of patients, announced today the closing of its previously announced underwritten public offering
with expected total gross proceeds of approximately $18,639,000 before deducting underwriting discounts, commissions and other
offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to fund its and its subsidiaries&rsquo;
preclinical and clinical programs and for working capital and general corporate purposes, including to acquire, license or invest
in complementary businesses, technologies, product candidates or other intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities offered by the Company consist
of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at
a combined price of $1.15 per Class A Unit, and (ii) Class B Units consisting of 15,723 shares of Series B Convertible Preferred
Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 13,672,173 shares of Common Stock, and Warrants
to purchase 13,672,173 shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance
and will expire five years from the date of issuance. The Company granted the underwriters a 45-day option to purchase up to 2,428,825
shares of Common Stock and/or additional Warrants to purchase up to 2,428,825 additional shares of Common Stock, which is 15% of
the Common Stock, Warrants and/or Common Stock issuable upon conversion of the Series B Convertible Preferred Stock included in
the Class B Units sold in the offering. The underwriters partially exercised the over-allotment option by electing to purchase
from the Company additional Warrants to purchase 1,807,826 shares of Common Stock. The offering, including the Warrants purchased
in the partial exercise of the over-allotment option, closed on October 15, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A.G.P./Alliance Global Partners acted as
the sole book-running manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering was made pursuant to an effective
registration statement on Form S-1 (No. 333-227400) previously filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
and declared effective on October 10, 2018. A final prospectus relating to the offering was filed with the SEC on October 12,
2018 and is available on the SEC&rsquo;s website located at <U>http://www.sec.gov</U>. Electronic copies of the preliminary prospectus
and the final prospectus may be obtained, when available, by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th
Floor, New York, NY 10022 or via telephone at 212-624-2006 or email: <U>prospectus@allianceg.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore
the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed
to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention
of <I>C. difficile</I> infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR),
and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying
cause of irritable bowel syndrome with constipation (IBS-C). The Company&rsquo;s preclinical pursuits include an oral formulation
of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody
therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria
(PKU). For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements
can be identified by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements with respect to this offering and the
successful execution of the Company's business strategy, including its intended use of proceeds from this offering. These forward-looking
statements are based upon management&rsquo;s beliefs, expectations and assumptions as of the date of this press release and are
subject to a number of substantial risks and uncertainties, many of which are difficult to predict and could cause actual results
to differ materially and adversely from current beliefs, expectations and assumptions from those set forth, projected or implied
by any such forward-looking statements. Important factors that could cause actual results to differ materially from those reflected
in Synthetic Biologics&rsquo; forward-looking statements include, among others, the underwriter&rsquo;s exercise of their option
to purchase additional securities, as well as risks and uncertainties associated with the Company&rsquo;s business and finances
in general, including Synthetic Biologics' ability to regain compliance with the continued listing standards of the NYSE American
by September 2, 2019, Synthetic Biologics' ability to comply with other continued listing requirements of the NYSE American, the
ability of its product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results,
Synthetic Biologics' clinical trials enrolling as expected, a failure to receive the necessary regulatory approvals for commercialization
of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a failure of Synthetic Biologics' clinical
trials, and those conducted by investigators, for its product candidates to be commenced or completed on time or to achieve desired
results and benefits, a failure of Synthetic Biologics' clinical trials to enroll patients as expected or receive anticipated funding,
a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics' inability to maintain
its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize
products, Synthetic Biologics' ability to achieve acceptance of its product candidates in the marketplace and the successful development,
marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete or non-competitive,
the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and remaining profitable,
Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and development activities,
a loss of any of Synthetic Biologics' key scientists or management personnel and the other risk factors described in the preliminary
prospectus relating to this offering and the risk factors incorporated by reference therein from Synthetic Biologics&rsquo; most
recent annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission (SEC) on February 22, 2018, and
its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is
provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vincent I. Perrone, Director, Corporate
Communication, (240) 660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)<BR>
Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv504760_ex3-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv504760_ex3-1img2.jpg
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M Q$!_\0 >@   @(# 0$               D("@0%!P8" 0$!
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M;J16L:\36$LNXA@:Z,:K_&,XW#;IKCHULBD1C'CDEBGH5Z$:/K"=(S<Q?VE
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MA%8\WO=8XI=6EW2E?5]Q'5?'J1(YNU X#[4W=3S,(&Z(:#Q:[W;JYWYBN;#
MN:<U2=BQQKG_ *B1V"* M'U@].QNPJN6IBLTAY&QL U: \?%J1&H/S.')W3M
M;R]T8%_+Q*A5/<AG(-5]4<862P;+7PN1G>N'$=D*:G&YJ\"LE8-C.0;:2GY&
MF5P;Q!FX_P ]Q568&+=M_P I),F2:)0*8%#'(FML)R&;?8FXSMOMA:IF!Z;)
MV..:S)> :U-S;*"?KL<&5_<V.HD?BZ%9.XM9G\46FI!&#V2,Z)'G7.50% !0
M"[A-$KRG\CLE;?L7V.'W'RU!1&GJL@&OE7!*H2+#'"R^\M6H#0*^9]6E"MFL
M;1&CR((0Y%#*M'HBH85$P,(3P;[Y<H#KC_E+HAL%(JY/A.!N,V^E+*1I12S[
M/+=CVQ?M*_DM9P9J9,]E=Z\UJ40[%.5F"Z93"T]SV((.7U"N+&V<Z',6R82\
M7*ITK7WCSI[A*.0D4G$,_;U;,\Z^B)E1\BDV<R:3B?%8#M!.W!LNB03>L54H
M!4RID^L?8+ZG=7&.@RMFUXO4\66+$,RV15=[O)=(X\<O/^'R"L(@2/*JBS\@
M13<*J*=A,<1 ,SALFHEEMRK!N/9*3%@Y]4G$8FY?NFSU%O7\";@K/W<5'MTU
M&TN !))I._=&2(T*HD=(3J'[%#A>AL9)1N0N>F+=R2[Z5BMV-(&3Q^Z7,Z-*
MOV7+I5FJZ\DX%%%9VF\=$%54Q2I'4'\_M[B'1+X?GO@(%Y4=@!,'<H<@'UT1
M,'Z]P"7V9$0[?X]PZ%W%8O+6/[,UD/M-/IN</)NZE?J8RE9%R5[)KR;B<Y(J
M?(L4_D7+-LBD9-C$G+^_TU>Q0!,AB%.8A5KW@R39H[+Z>D8.E7K0OUV]0_3<
MK-?9JJ";8:['6 S7UG'I^DX,<@#YF\P*!OQW[ %>WBZ",'8;:.5CV3Q9F;[!
M/'RBPG'?R*\R,:XR9N^JV8NFJR[*Q*.7! (LN911-0IR#ZW?]Q##KT-QKJ%7
MQ+F6,;K&73=\,#.R&.<.PE<6[F'LEG=(@'D;N1NXE3$*/?L(%_0/TZ@<!]E0
M&H<G/UXS/#'(W+M.B94Z2!7"G8F=M6#E)Z1ED .110H%-^\.P"(_GMVZH2KI
M(Q6K>[O,U%6=P%B<,^1O16/DY.6=O'BRJAN8S&P&ESO$@C5EGZ ?N*8Q 3\O
MU3$O8.B/BC5F54Y&_L45)>8<.9J1RC'Q#>:<O#*.O?RO)IA--BZ-)F9**M%D
M#.2=G!6RID/'N"1^WB+JG <VSA1KO9R6JD?D8)_\2VF)'8G'_P"UB;D0JWNH
MPA0*8RBKY(/ I2AY&'\!^>@7ADOM_P C?V@/Z#C;'H_]>P[1ZV#_ -^W0->V
MT;/9C@5YUF[1VFG*Q7(KO>]G6J[J5/'Q_L=U(28<1T,L@1@+A!W#*(K>)RG;
M*.7*H+%[B<A01;".6$IJI]32&D5E6ZSW<C+LFJO_ !=[.QPD/N)CQ)-$S!F+
M)F^47>@!!9$735](WD!?#H/8\NL'9[.MPORDC-G5K5@WYY (!\T<S1(XYK2_
MY&DUWLXNZ?H*Q+0ZL2Z33%ZMY EX=S$$@#W(91P%713)',OS^V^0=LHYZK+Y
M4CHFL,4GR[ D,WV$R*@LZCGKQPZ&/;,7+1(ZK<#%(NXDCJ$(4I!*!41%FJ^4
M,-T2II/Y2//.8 ^NO26J5E9MH@*N,CO1L,P,*)7D@DW4B7JJQI--995N54KH
M/T P&$E,*RQ8(HG$?N[(*MI67AIC[!N0"*+U9LPFUR,E.2NE2'NT&[IPW;/D
MEP: BF4JR7J++)E\RE$1Z+S! TB<3R_VXSBF9(3S\J84C@ &2$W(\T'TS '<
M ,01["']0Z)-&<UZ]V0>.K*9'ZTE[T/JU8=)7(E*"72DA8DV!R_5K+(.P- ?
M%O&**#B/.DH5+S28JF5\_P!PN.BGU<=L>*W.1SW3WJUU$I&NA=?"/ACID=*&
M:X3LK\922;BL987JX.P3<*^($,N00 >Y1#H*L5"74;[5?5$42$"F-+75 1,1
M-0/3<[VY';+!XJ%.4!,BJ8 -V\BB/<H@8 $ S.(6)D/]Y=&G.S'XDGV![C$F
M-X,C219$^L.USM,OJF+\BBQ,W(/[2CZ"J@=SAY)DZ"/>@LG9'UIYP5%F+M.8
MLVZFB#6Q/D4TV;JJ*R?*U .WT][!\BL0RL;+)II V4(( HJ'F E*8HA88WU*
M^1Y5<UK S,:-?\A_UVV"CY1-T"0.&KK9AX9NW53;*-5'!2G3%0BBB7@FH40[
MB8I1)CW*K_8"7&2QO]I*53>KMW),UXL+;&TF58"NX97D/E1,F1)PS543F$7K
M=IZ)C+IF*V%8O@;R Q"K8/!* _[C=.?\!'Z[>I'81#^NQMZ$![?CN'YZ!)W$
MA652Y<SG)6265?W&0^QKI]!VOV+A-HV,[JY=T9@DJQ.Q]K((!*SDH[ X"5-%
M1!("%#L*I0(U>6/SC;*X_P!>#FA?I_\ J^^ZGZL-1^RN5X;E$^O.58S/XDVT
M,85, !<K\KP=@-7@>&64,<6OLQ;"EZ8 4#E.!Q,(@)>U2Z).X^WLO-;A\N\U
M8R"VFGO)-Q]GEFBK-PQ53=O.8O'JK@!;J)]F@-Q0\134,"G[@[ ;L<2AL\#R
M<L^Y*N?>5GF[A.66SE6G#YL#-9!R"A>4O"/9,K(X>N4XIE#Q)V[C^/Z]2[BG
M#<VSR,1WAY*VCV)!X[=<5^C!HV43>.&SF*<(<B4$4A00 3M'C)TX<)'7*<GJ
M"5 "IG3$QC=4+OR(@JZY(_L\M6Z2JZ[G'N.&Z*""9UEUE5]J-:DDTD44RF45
M54.8 *4H")A'L ="FNY_L;NP?7AYI[0HR(5W8-V>0-VY:,P550;>^WK5:N#)
M"(F5%!JAW4$QA_ %$1_ = DFH(-)G5OZBT0P)[!=SNADI-8'#ARY*LY+N#CL
MCA_W0%FJ@@N?L'HD.!B=OP;\]^@R>2]N_FLT<%=;1E'#%M([T;L^B ^HY9LY
M!URBBT"3^.!PW16<II@4!'R(8Q" 7R .W94AA?UKF;-YR:\_D\H@";YO=+JR
M;>BHHDW09S&><ZO'J(-2&*W-Y+0[?P,)!,F!! H@!C )46Z4X=V+'E/CE8^7
MCYM+&/UQH1\M:8>/:1DDNIN_FQ:&D(=BV6E&[ZN! /FB!SJB<Z[I%?S(3\IE
M)TQ:"9061.)O/$5:$FQ#7G[#DTQCW$>S"'<,)F9Y):6(/*]&.$UD63\&9G!$
MV[@Q"%34.4Y^_P"I5<'*]HB:_)_:E4F6<@[_ )3F^)JL8$:9F4&<Y+<B$G(L
M7S[WJA!-%H$B52J D!G F4)XE[>1B@X#'\$<VDFS,**-V-Z7U7=6I C8)UI_
M)R";)NQL^8XR8NO9?#&$04%N!^XPW9KX>0>GT%H72'63/V(>2#E_SK?:<RAL
M/[+7C6";P=,J2,,\>WC^ X34K%O?>,=+/'T/&1TL=)GZ#YHV5,N510@G3'\
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ML_8*=UK4"R"OOAG7%LI@J'D[MC8DI;J15]N+#D*<L$>5O<O;,%T*^W8O4T9
MS8ZC-V8Q2B=,Q0"P7Q.Z6[-X%S-KM><Y8]?4Q*A<,FKVJUH<+RU9?D8YHIN7
M;Q9;13BA!R$@@Z>5V"%FHJX1$[(WN"@510PF[ IOC2XR-\,(.+!-9=U[O,$[
MM/.7@G:))]-R](EK%(8*I\%L3'6#)5B4@)UP1LU:REG:&4(J5%4YI$JJ2/IJ
M"($KGUUXZ=X9S#^4")ZHY6&?G^'[&6(H6*%C''E6V6&_([)Y;G,9&:MY8Z;N
MW-,='))+()BJ1-L4#@?L<OD71D_.EH?N'MIR <,V3<!83?7_ !3K+G*/NN:+
MNRL]4CBT>,',.#K'(+2<-.3$7)N6K.MT9TZ(=D1V=8Q3) 0#@0% 6UKIQ;\@
M%+V@Y-<O735Z\U^J;,\@VE66L1/3V:C3#F:QUC_D_@<LWB>DX&OVR4>0Z5?Q
MI&&GE5GR:)T8X@^'<RHD$,BI<6?(#$[X<QNP\WK3;8W&>T&9:E,X0?DG*5+R
M]UB&W(7B+(:\BE7X&RRDQ$M6^/ZVZF53OD6Q2,4Q-W$0$ @G/RUZ.[8YSW$W
MCO>)L'W.[U#(G'EIWBNDS\.W:'C[)D*J;V05\M%5C3JNTCJR==I;!64>@)2E
M;LB@H80*8.]$1+-Q\;WP?(MS>9<8:X9-1Q]M<OAFO8$RE#LJG88>6?([0:WV
MEU9DX,+*$\[B*S7H=[)N@!D?LA'."F*!B"'03WR%IYL]*\%7*3KW'X/N2F;<
MO[,[Q7/&>+&C%(]DM]8N^W4G=:A*5YD9V?W;.QU0GOV/[_-PW,4Q 'S+W!.F
M-^+/D7BJY]9M:0UQRXVA=5LYV>=V0K+IQ# AA%.6V]@LBQ]KMU9"4+(10R./
M6*KEP\$BQ4T6R2!_25$J:@=QW'XOMY,J9/X>K14=7<D2+C73=7:K(&<I!&:H
M_P -C_&MRY!&64:K)NTE)]-W+KRU-54F$5H_W2:D?_X^91 !\2;^OGHMNKKG
MN'S'96V9UYN&'X//]J>KXWDITL46+N[]UDC,=H=_Q'V4W++244G'VID=-T4Z
MC<X+@0JISE.!0X-@#0S?"6@<7?S'6C*573CX3@K@6:-D;0<D6)B-<=O\QY!S
M2X<PSA:)0BFM K,LE*RK!T *(E>D4,8YUREZ(FWB[3K9NI\<MEQA9\*9#:9%
M7YR&V>F=4:Q:\C+N<1FWTJ5U)DDZ<9.,BJTP]/:+2AGB@/$/9$]8S<Q>RA"D
M%9^XC>4I29YYU:UIID:?KVV&=X6QX>E86P4A:1OU?:[GO<BMGE<KY).2D)>*
M<4^1^0=>0,5VR21!\O\ VD &:TSCZWKC].<]XV>:_P"66^3;+]>W776"#AC2
MT&6:E,XUK-^?)&>Q.WL8/30ZDS$U2=9'68BJ DBW23;U/,P'Z"[KT!T!T!T!
MT!T!T!T$.]_]LD]&M/,[[6*8_L641PW3%;&C2*PB=61F':[YG$L1<G3(H=E!
ML'LBFXDG(%,+5@DLKV$2=A#@6.^2)UDBWZGLF6MF6:M1=G]0,Q;6(SUW;IP=
MXJ;O$;K'Z#O#RN,4V[Z6>7B79WY!Z@95RU05; 3T?6.90J00;I?/8ZON+L8Y
M8A]/;2S@W[W)E\V&C764X)_/:W:UXKR=0L2V/(%PB8JLK/W.70LV04G T%1)
MF_0C(B17.[_MH%7#O&Q_,(."6&QK6#UMG,C7?!.WB&KT95&N2:]6FUSAX?56
M%W#R%EAU9)B(&,J,+4,2KR!09. 64<2+9%(5DDUS*(DR&_,G!A.[8-WNMN0U
MJ]@32^H;U8N<52VTBYW#-V$K>R=?&/W%'AI(7F.I.7DFYE(UJ[</%W,2BJ\5
M*W-Z#=<J>NB.U:>[VI6$MJD,87'#K3,U3"TLJ#?/:#8HIL60>QA')SM! CB(
MESL#.XUP8B)W<<L@N*9 5 H!+CH#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H,"5
M^+^+DOG/8?"^P>?,?*^W^+^+]NI\A\E[S_*>P]IY^MZO]OT^_E^._0+0VO3I
MQ]N-:ABG6R*&90U2WK+B,F!V&%W=94A#P&%0LZKI7*<DR02RFWE_X^-((!#P
M2SX50ECI- \A!'5F0T.&1JW^HLGR,$NR$EGH>1O^7P6MZLK*4G_5[5@F5T]U
M1JMB1Q] T0<A#3U&)\4?).@@ F$VQ1;"Z4 .H[V(:/G8[[A893>5M=C\A[0]
MV/@R!P$]O#?(Y>-:M!F!MAA._6-A"/,-+Z; [&PKSID)U*3,Y")247*Q$P3O
MU#3UM)O7+F.\V'<W-32."-JRCF2-P,RPDST,"=I &1PTYQ3*R%TDH UD^+,Y
M4R0DUL0)B8J9!1!4PD.PA?A_AXG^._&?Q_XQA\%\+[7X?X?VJ7QGQ/L?\E\9
=[+P]#T?[7I>/A^WMT5L^@.@.@.@.@.@.@.@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tv504760_ex3-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv504760_ex3-1img1.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0/+:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C8M8S$S." W.2XQ-3DX,C0L(#(P,38O,#DO,30M
M,#$Z,#DZ,#$@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-$$T-SA%03%#13E%,3%%.$(X1C9!,$(S0C,S
M040S,3,B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-$$T-SA%03!#13E%
M,3%%.$(X1C9!,$(S0C,S040S,3,B('AM<#I#<F5A=&]R5&]O;#TB061O8F4@
M4&AO=&]S:&]P($-#(#(P,3<@5VEN9&]W<R(^(#QX;7!-33I$97)I=F5D1G)O
M;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.C V9#AB-V)B+6$X860M-#EF,"TX
M,&0W+6$Y.6$V,S%D-C(X,B(@<W12968Z9&]C=6UE;G1)1#TB=75I9#HY.60X
M9#%E9"TW93<Y+30W-30M8F$S9"UC.3(Y-S9D,3,X93$B+SX@/&1C.G1I=&QE
M/B \<F1F.D%L=#X@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY#,C Q
M.#$P,3$M,#4R,RTR,#$X,3 Q,3$P-#$Q,3PO<F1F.FQI/B \+W)D9CI!;'0^
M(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO
M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S
M+C  .$))300$       /' %:  ,;)4<< @   @ " #A"24T$)0      $/SA
M'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L A  ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(#
M P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" !3 %,# 1$  A$!
M Q$!_\0 A    04  P$!            "@ '" D+ @4& P0! 0$
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MQ^N0T-<+$&RF=]7Z;9)!@LBIG&$]T]L@Z8RN:PY(P<Y.FNXV.V=H@63$U[5
M0>-;-Y?+Y4X 4E4B,3(:,74AW,+L2I@W)6[UXH/%;-4UT<;)YVV A+L;_<,W
M=P%LYCQ9[DDOMB<<89)NWB=?3B7INY ;HLT*DC>&[F4CDC40-GJ5&_$/&SYN
MU5=;#G"&ZK=/;.JR.P:74>D .6 0LIC)5B=CDC%#SH$V+<)O!I<,6:)/AA,>
M[1VV2<LGS-?15)37.==]-L9Q^&? =QX" _<VYWP7MN\+KDY739)L2<0D+\97
M\5<*JH_7%HR'"C""Q'11'7=5-$B6SA1UOKY918H+J>>.CP&078,NY ]P[E4
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M)>ZZ?C_+ZB^'_P ']E_ _,_CZ/G^'@*4>[.\F=<]^[N#* )UO7;IY+EI$Z<
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M*/4D\5W051T\!"KCC77&16SZQY#\QN2E;3Z$P&!-)JI19X?(I>0?R6<RN3'
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M*C]0OUYZ/P!3I^DOK;_PWY/I\_<]?[_VGJ]7[7EX*-2XD?Y3#/\ Y=_YEO\
=Y(_RF_F)+^6?TO\ K_O'K>%$82B\ O +P"\!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tv504760_ex3-2img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv504760_ex3-2img1.jpg
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M Q$!_\0 A    04  P$!            "@ '" D+ @4& P0! 0$
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MQ^N0T-<+$&RF=]7Z;9)!@LBIG&$]T]L@Z8RN:PY(P<Y.FNXV.V=H@63$U[5
M0>-;-Y?+Y4X 4E4B,3(:,74AW,+L2I@W)6[UXH/%;-4UT<;)YVV A+L;_<,W
M=P%LYCQ9[DDOMB<<89)NWB=?3B7INY ;HLT*DC>&[F4CDC40-GJ5&_$/&SYN
MU5=;#G"&ZK=/;.JR.P:74>D .6 0LIC)5B=CDC%#SH$V+<)O!I<,6:)/AA,>
M[1VV2<LGS-?15)37.==]-L9Q^&? =QX" _<VYWP7MN\+KDY739)L2<0D+\97
M\5<*JH_7%HR'"C""Q'11'7=5-$B6SA1UOKY918H+J>>.CP&078,NY ]P[E4
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M)>ZZ?C_+ZB^'_P ']E_ _,_CZ/G^'@*4>[.\F=<]^[N#* )UO7;IY+EI$Z<
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M*/4D\5W051T\!"KCC77&16SZQY#\QN2E;3Z$P&!-)JI19X?(I>0?R6<RN3'
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M*C]0OUYZ/P!3I^DOK;_PWY/I\_<]?[_VGJ]7[7EX*-2XD?Y3#/\ Y=_YEO\
=Y(_RF_F)+^6?TO\ K_O'K>%$82B\ O +P"\!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tv504760_ex3-2img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv504760_ex3-2img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +0"M P$1  (1 0,1 ?_$ '<   (#  ,! 0
M       )!@<* P4( @0! 0                     0   & @$$ @$"! ,'
M!0    $" P0%!@<("0 1$A,4"A4A,? B(Q9!%QEQP3)"0R0T)34W>+H1 0
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MWUBT6<P6=B#Y6VV.]>O&TBWDFTLWI>>$T(5J1<5D!C*^"KMCYF4+[BMT5$"
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M:;,ZC;WJM#$6()1#R15(82E$1* >A_X_?H#^/W_COT!_'[_[OVZ Z Z Z Z
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tv504760_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv504760_ex99-1img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 3P$$ P$1  (1 0,1 ?_$ ,0   (" @(# 0
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MTM&3L)*MDGL7,0S]K*14DS6#J1=L)!DJNT>-E2^I5$SF(8/@.M @J:,*$:W
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M(L9.*>H%=,Y)@Z0=L738X=15T':!U$%4A+_B PAKO=8Y&PREE'DL;/%<8^5
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M_"'^FWW_ +==&_\ G9>_]#GY=ZQ_F/YG\@ZNH]?HT]3J_P#8?PM4\_Y50?\
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MJH]-78#K8>!AE56:O)0VJWIG9R&.FH!DE$SF3424+T*)*$,)%$U"& #$43.
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M(!(J#0D"H\!IL=Q,]8[I[@9S<V,$@QN1R]Y<Q"0!7$<]Q)*G6H+ -TL.H!F
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MO#AQ/$7@WA]3_:6ZL=W;FV5@LS;]S=[8WY.^-S<0O86ZR*JSO;A!ZKLU*J'
M'50_  59KMZJ3&_4BX4:366;QMSJ\_57[AOT^X09V"*=Q+E=OU_+WT478F)O
MZ=0!JP&5Q\66Q=SBIR1!<P21,1S"R(4)'M /#5(]M9RYVQN*PW)9JK7>/O8+
ME%;\+/!(LJAJ>!*@'V:41C_Q[\FXB?XS1MXROAJ9QUQ/O<%-4+Z)4Y^.O%KK
M+.:.[<M;5,+@LD@\C(PYB,6R0J-NZH;K/Z=T:[X;L_OFVN\%!E<CC9<+MZ[1
M[?HAD6>6)6-1,YJ 50T15JM2:G][5[-T?5/V=OL9O"\VW@]P6^[-\8R:*]]:
MYA>SMKAX@JM;1+0LDD@!FD;IDZ5'2O[@;1D^NR%PQID.I1)FQ)6TT:VUV,,\
M5.BS+(3<!(1C(SM9-)=1)L#ET7N&*0YBEW$"B/IJP6>LILE@[W'6_3\Q<6DT
M:]1H.IXV5:FAH*D5-#P\-4<V;EK7 [OQ6<O@YLK+)6T\G0 6Z(9TD?I!(!;I
M4T!(!- 2.>M,<+\/6S /%_$&'KTK#+VRC0#Z,FE:^\<2$,=RYL$Q*)BP>.V4
M<X72]L_( B9!,0-N&VP;BV.V.V\CM#8>-VWEC$<C:0LKF-BR5,CL.EBJDBC#
MFHXZD+ZA-^X/NAWESV_=M+<+@\E=))")T5)0JP11GK17D53U(> =N%#7PU'+
M._%'D6YS[>L[\9LD8VK<AF#%;'%61H?)\/./B,&D6F+6/L-2>0!%%$I!%ITB
M!%PZ"*DZA!0#=)&=NS8&]'W==;LV-?6,$V1QZVEPETCL%"<%DA:/B& /)N (
MKQ!H)8[9][NT\/;#&]M.\&(R]W:X'-ODK"7'2PH7:0]3P7*3$ H6KQ0U*F@*
M%:M+3C'A0>.^"\?8?5LKZXO:C%N$Y6SR K]^9F).1>3$HZ3(Y<.ET697S\Y&
MY#*&,1 A $1'?4@[&VO_ ";M2SVV9WN9+:,AI6K5W9F=SQ)('4Q"@DT4 :@[
MO'W$'=;N3E=^I9QV%O?S*8[=.FD44<:11J2JJ"_0@+L% +EB!2FHP\BN.7+&
MVWO(<OA?-=-<8WS#CXU"MV+,VLK#8:S2U%6AH]S9,=LXD%6J#UVV.911)PGT
M>X,8P]PHD!)C[RV9W!R.6O+C;.4M3A<E9^A-:WRR210FG29;94J S#B584ZN
M)J*!9C[4=V>Q^"VSBK#N%MW()NW Y3YVUR6(>""XNP&ZUM[YY:,R*P"JR&O0
M !TD,7E5QOPTVX]X,QGAAK,KV(E K2$,M..$0;&DWIUW#^1=IM0.K[5JH_>*
M=E(3'%-'I*)C" B+\V5MJ/9VU;';,<IF6S@"%R*=1J68TXT!8F@J:"@J>>H4
M[M]P)>Z?<G,=P9K=;1LI>-*(5/4(T"JB*6H.I@B+UM0!FJ0 #36[=.C4=:Z6
MR5R"M\!,5:SQ3*<KT_'NHJ9B)%$KAE(1[Q(R+ALX2-\2'(;T$-C%'82B @ Z
MT\AC['+6,V,R423X^>-DDC<55T84*D>1'[1QTHXG+9+ Y.#,X:>2VRMK*LD4
ML9Z71T-593Y@_81P(()&JO?-_@!>>-LG*WO'[.3N.#7+@[E*0034?SF/TUC;
MA&6Q)(@K+1+<P]"$H!13,3I*X[:FPJ<T>\OT]Y;8%U+F]O))=[+9B015I;4'
M]R8#BT8Y+,.%*"2AXMV5^G/ZH=M]W+.#;6Z9(<?W(10I0D)#?$?^9;$F@E8<
M7MR>H&IBZEX*M(),! ! P" AN AL(" _ 0'?U =5W^5KQ'+5O#:4-"#77GZE
M_%_T_OT?*Z/E1Y:/J7\7_3^_1\KH^5'EH^I?Q?\ 3^_1\KH^5'EK)*= 6C(-
MI@J32H9[8K59I!"+A(:/2[KEX\7,!0^'RH-D"[J++'$$T4BF.<0*41TH8G;^
M2SV3APV'A>XR=PX2.-1Q9C^@*.;,>"J"2:#21G\IA=K86YW%N&XCM,)9Q&2:
M5S145?UL?PH@JSL0J@D@:M]\-^-C#B]A6%H9EV\C;9)<]DOTTW*':D;3((HD
M<-V9Q(54T5#MD4VC7K]3$2%00 RA@UUA[0]N+;MCLR' *5DR<C&:ZD')YW Z
M@OCT1@!$KX+U<"QUP@[_ '=VY[S=P[C<P5HL'"HM[*%N:6R$E6<5(]65BTLE
M.1;IJ0H.I2)MFZ2KA=)!%-=V9,[I8B9"JN#))E12,LH  944TB 4NXCL4-@U
M)RQHK,Z@!VI4TXF@H*^=!PU"[32NBQNS&- 0H)-%J:F@\*DU-.9U[]>]8]&C
M1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:
M-&C1HT:-&C1HT:-&C1HT:-<9Y[/V;KZA[;V'ME_?>\[7L_9]HWN?==_^3[;L
M]77U_+T[[^FO$OI^FWK=/H])ZNJE*4XUKPI3G7A36:W]?UT^5Z_FNL='17JZ
MJCIZ:<>JM*4XUI3CI&O(_B)XX\N/9*P8XY.8,P;=E5G)GB%?RIC9[27LCUJ"
MJ$C35K0T"*7%QZ*#'K- +ZB9(QM5 WWVR[![FGDO<+N##8?+DGJ$5Y:&!FXU
MZX#*.@UY^FR>U2==(NTG??ZM=BVT.+W;L[<FY-N*J]!GQM^EVD=!3T[L6[>J
MO3Q43I+7A1P-*9R'PZL%-76&L<@^)648Y,.HCNK\C,:0[XY1$?\ O(BVV"&.
M50 #U*DLM\?01^.JX9KM2<8Y_+\]MG(0>!BR=I&WVI-(GZ&;[=7BVKW]QF?C
M49G:N^<+='FMQ@<A*@/LEM8)>'M9$]H&H]+8UNB#@S8RU!.<I^WW$,QX=7;&
M'JZ>HKI._&0%,1]>KJ -O73+;;%RCF,RX\D&E1?6)'WBXI3VZE2/>&WY(A,%
MR@4BM#BLJ&^U39=5?934CL4\.9"]NVREXY&<5<001Q(=P\L6?<9V*=[(F+W
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-:U.NJF:-&C1HT:__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tv504760_ex99-2img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv504760_ex99-2img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 1T# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
